Original Article
A Randomized Trial of Maintenance Therapy for Vasculitis Associated with Antineutrophil Cytoplasmic Autoantibodies
N Engl J Med 2003; 349:36-44July 3, 2003
- Abstract
Background
The primary systemic vasculitides usually associated with autoantibodies to neutrophil cytoplasmic antigens include Wegener's granulomatosis and microscopic polyangiitis. We investigated whether exposure to cyclophosphamide in patients with generalized vasculitis could be reduced by substitution of azathioprine at remission.
Methods
We studied patients with a new diagnosis of generalized vasculitis and a serum creatinine concentration of 5.7 mg per deciliter (500 μmol per liter) or less. All patients received at least three months of therapy with oral cyclophosphamide and prednisolone. After remission, patients were randomly assigned to continued cyclophosphamide therapy (1.5 mg per kilogram of body weight per day) or a substitute regimen of azathioprine (2 mg per kilogram per day). Both groups continued to receive prednisolone and were followed for 18 months from study entry. Relapse was the primary end point.
Results
Of 155 patients studied, 144 (93 percent) entered remission and were randomly assigned to azathioprine (71 patients) or continued cyclophosphamide (73 patients). There were eight deaths (5 percent), seven of them during the first three months. Eleven relapses occurred in the azathioprine group (15.5 percent), and 10 occurred in the cyclophosphamide group (13.7 percent, P=0.65). Severe adverse events occurred in 15 patients during the induction phase (10 percent), in 8 patients in the azathioprine group during the remission phase (11 percent), and in 7 patients in the cyclophosphamide group during the remission phase (10 percent, P=0.94 for the comparison between groups during the remission phase). The relapse rate was lower among the patients with microscopic polyangiitis than among those with Wegener's granulomatosis (P=0.03).
Conclusions
In patients with generalized vasculitis, the withdrawal of cyclophosphamide and the substitution of azathioprine after remission did not increase the rate of relapse. Thus, the duration of exposure to cyclophosphamide may be safely reduced.
Media in This Article
Figure 1
Kaplan–Meier Analysis of the Time to First Relapse in the Azathioprine and Cyclophosphamide Groups.Figure 2
Change in the Glomerular Filtration Rate from Study Entry to the End of the Study (18 Months) in the Azathioprine and Cyclophosphamide Groups.Article Activity
- Article
The most common primary systemic vasculitis syndromes — Wegener's granulomatosis, microscopic polyangiitis, and vasculitis limited to the kidneys — are associated with circulating autoantibodies to neutrophil cytoplasmic antigens (ANCA).1-3 It has been suggested that they be grouped together as ANCA-associated vasculitis because of their histologic similarities, the absence of immune deposits in all of them, the potential contribution of ANCA to their pathogenesis, and their similar responses to immunosuppressive therapy.2,4-12 Renal involvement is common and is typically manifested as rapidly progressive glomerulonephritis; it results in either death or end-stage renal failure within two years in more than 40 percent of patients.4,6,13,14
We have previously subclassified ANCA-associated vasculitis according to the severity and extent of disease at presentation and have defined generalized vasculitis as vasculitis that threatens vital-organ function.2 The standard therapy for generalized ANCA-associated vasculitis has comprised at least one year of corticosteroid and oral cyclophosphamide therapy.2,15-19 The resultant exposure to cyclophosphamide causes hemorrhagic cystitis and increases the risk of bladder cancer and lymphoproliferative disease, myelodysplasia, and infertility. The vasculitis returns in 50 percent of patients, often after the reduction or discontinuation of therapy.14,17-19 Azathioprine is less toxic than cyclophosphamide and has been used as an alternative immunosuppressive agent for the maintenance of remission in patients with vasculitis.14,20,21 We undertook a study to evaluate whether exposure to cyclophosphamide could be reduced in patients with generalized ANCA-associated vasculitis by the early substitution of azathioprine at the time of remission. Relapse was the primary outcome measure.2,5
Methods
Study Patients
Patients were recruited from 39 hospitals in 11 European countries. The study was approved by the local ethics committees, and all patients gave written informed consent.
Study Design
All patients received the same remission-induction therapy, consisting of cyclophosphamide and prednisolone. Those patients in whom remission had been achieved by three months, or between three and six months, were randomly assigned to treatment with azathioprine as a substitute for cyclophosphamide (azathioprine group) or to continued cyclophosphamide therapy (cyclophosphamide group). Twelve months after study entry, the patients in the cyclophosphamide group were switched to the same azathioprine regimen as the azathioprine group was receiving and continued to receive this regimen until the end of the study, 18 months after entry.2
Eligibility Criteria
Criteria for inclusion in the study included a diagnosis of Wegener's granulomatosis, microscopic polyangiitis, or renal-limited vasculitis; renal involvement, other threatened loss of function of a vital organ (lung, brain, eye, motor nerve, or gut), or both; and ANCA positivity. ANCA-negative patients were eligible for enrollment in the study if there was histologic confirmation of vasculitis.1,5,22,23 Criteria for exclusion were the use of a cytotoxic drug within the previous year; the coexistence of another multisystem autoimmune disease; hepatitis B e antigenemia, hepatitis C, or human immunodeficiency virus infection; a serum creatinine concentration of more than 5.7 mg per deciliter (500 μmol per liter); cancer; pregnancy; and an age of less than 18 years or more than 75 years.
Drug Regimens
Both groups received oral cyclophosphamide (2 mg per kilogram of body weight per day) and prednisolone (initially 1 mg per kilogram per day, with the dose tapered to 0.25 mg per kilogram per day by 12 weeks).2 The dose of cyclophosphamide was reduced by 25 mg for patients older than 60 years of age, and cyclophosphamide therapy was discontinued if the patient had a white-cell count of less than 4000 per cubic millimeter. After randomization, patients received either continued cyclophosphamide therapy (1.5 mg per kilogram per day) or azathioprine (2 mg per kilogram per day), with the same dose of prednisolone (10 mg per day). Beginning at 12 months, both groups received azathioprine (1.5 mg per kilogram per day) and prednisolone (7.5 mg per day). Prophylaxis against corticosteroid-induced gastritis, fungal infection, and Pneumocystis carinii pneumonia was recommended but not mandatory.
Evaluations
Study assessments were performed after 0, 1.5, 3, 6, 9, 12, 15, and 18 months and at the time of relapse, if it occurred. The assessments included a complete blood count and measurement of the erythrocyte sedimentation rate, C-reactive protein, alanine aminotransferase, serum creatinine, and glucose. The glomerular filtration rate was measured at entry, at the time of remission, and at the end of the study. Disease activity was measured in terms of the Birmingham Vasculitis Activity Score and the Disease Extension Index.24-26 The Birmingham Vasculitis Activity Score includes values for 64 predefined items derived from clinical or radiologic evaluation in 10 organ systems.24,25 Each item carries a weight (ranging from 1 to 9), and an item is scored if the investigator believes it to be present and caused by active vasculitis. Positive scores are subclassified as scores for new or worse disease since the previous examination (range of scores, 0 to 63, with higher scores indicating more active disease) or as scores for persistent disease (range of scores, 0 to 36). Cumulative damage from any cause since the onset of disease was scored on the Vasculitis Damage Index at 0, 6, 12, and 18 months.27 The range of scores on this index is 0 to 63, with higher scores indicating greater damage. The Medical Outcomes Study 36-item Short-Form General Health Survey (SF-36) was administered at each assessment.28,29 Adverse events were graded according to predefined criteria as mild, moderate, severe, or life-threatening.
Disease Definitions
Diagnostic definitions were adapted from the 1992 Chapel Hill Consensus Conference on the Nomenclature of Systemic Vasculitis1 and a previous European Union study.5 Remission was defined as a Birmingham Vasculitis Activity Score that indicated the absence of signs of new or worse disease activity, with persistent disease activity for no more than one item. Major relapse was defined by the recurrence or first appearance of at least 1 of the 24 items on the Birmingham Vasculitis Activity Score that are indicative of threatened function of a vital organ (the kidney, lung, brain, eye, motor nerve, or gut) attributable to active vasculitis. Minor relapse was defined by the recurrence or first appearance of at least three other items in the Birmingham Vasculitis Activity Score. Determinations of remission and relapse were made by the investigator and validated retrospectively by an independent observer.
Statistical Analysis
Randomization was performed centrally with the use of permuted blocks of four within each country, with stratification according to diagnosis. Primary data were collected in record books and submitted for centralized computer entry. The data were validated against the record books before analysis (with the use of SPSS statistical software, version 9) by two data managers who had sole access to the data.30
The primary end point was relapse, either major or minor. The predicted relapse rate for the cyclophosphamide group was 25 percent.14,19,20 The study was designed to detect an increase in the relapse rate in the azathioprine group of more than 20 percentage points — that is, from 25 percent to at least 45 percent. A total of 146 patients were required in order to achieve a significance level of 0.05 and a power of 0.8. The effect of treatment on time to relapse was examined by Kaplan–Meier analysis with the use of the log-rank test. The demographic characteristics of the two groups were compared; categorical variables were analyzed by Fisher's exact test, and their effects on relapse were assessed as covariants in the Kaplan–Meier test.
The two groups were compared in terms of the secondary end points reached between the time of remission and the end of the study. The rates of adverse events were compared with the use of two-by-two tables and Fisher's exact test. Changes in the glomerular filtration rate were assessed by analysis of covariance within groups, and linear-regression analysis was used to measure the correlations and the differences between groups. The areas under the curve for the Birmingham Vasculitis Activity Score were compared with the use of Student's t-test after logarithmic transformation. The values on the Vasculitis Damage Index were compared with the use of the Mann–Whitney U test. The mean scores on the SF-36 were calculated for each of the eight dimensions according to the Likert method of summated ratings, and the groups were compared in terms of the changes in the scores over time with the use of repeated-measures analysis. C-reactive protein levels and erythrocyte sedimentation rates were compared with the use of Student's t-test. All tests of significance were two-sided, and P values of less than 0.05 were considered to indicate statistical significance. No interim analyses were performed.
Results
Patients
A total of 158 patients were registered, 3 declined further participation, and 155 entered the trial. There were no significant differences between the two groups in demographic, clinical, or laboratory features at the time of randomization (Table 1Table 1
Characteristics of the Patients at Randomization.). Histologic confirmation of the diagnosis was available for 132 patients and was subjected to central review.31 Clinical remission was achieved in 144 of the patients (93 percent) — by three months in 119 patients (77 percent) and between three and six months in 25 patients (16 percent). These patients were randomly assigned to cyclophosphamide (73 patients) or azathioprine (71 patients).Deaths and Withdrawals
Seven patients died during the remission-induction phase (two from pneumonia, three from pulmonary vasculitis and infection, and two from stroke), and one patient died (from stroke) during the remission-maintenance phase. One patient was withdrawn from the study during the remission-induction phase, and five patients were withdrawn during the remission-maintenance phase — two in the cyclophosphamide group (one at 6 months and one at 13 months) and three in the azathioprine group (one at 7 months, one at 12 months, and one at 13 months). Three of these patients were lost to follow-up, and the other three were withdrawn from the study by their physicians.
Relapse
Eleven patients in the azathioprine group had relapses (15.5 percent [95 percent confidence interval, 6.9 to 24.0]), as did 10 patients in the cyclophosphamide group (13.7 percent [95 percent confidence interval, 5.6 to 21.7]; P=0.65; difference, 1.8 percentage points [95 percent confidence interval, –9.9 to 13.0]) (Figure 1Figure 1
Kaplan–Meier Analysis of the Time to First Relapse in the Azathioprine and Cyclophosphamide Groups.). Five patients in each group had a major relapse. The mean C-reactive protein level at relapse was 26.1 mg per liter (95 percent confidence interval, 0 to 55), and the mean erythrocyte sedimentation rate at relapse was 49 mm per hour (95 percent confidence interval, 23 to 75). Relapse was less common among patients with microscopic polyangiitis (4 of 52 patients [8 percent]) than among those with Wegener's granulomatosis (17 of 92 patients [18 percent], P=0.03). No other variables at entry influenced the rate of relapse.Adverse Events
A total of 218 adverse events were reported in 84 patients (Table 2Table 2
Adverse Events.). Fifty-five percent of patients (85 of 155) had at least one episode of neutropenia. Severe or life-threatening events occurred in 15 patients (10 percent) during the remission-induction phase, in 8 patients in the azathioprine group during the remission-maintenance phase (11 percent), and in 7 patients in the cyclophosphamide group during the remission-maintenance phase (10 percent; P=0.94). Of 33 infections, 17 (52 percent) were associated with concurrent neutropenia. Allergy to azathioprine, manifested by fevers, chills, and a rash, resulted in its discontinuation in five patients (7 percent).Renal Function
There were similar increases in the glomerular filtration rate from study entry to 18 months in the two groups: an increase of 17.5 ml per minute (95 percent confidence interval, 11.9 to 23.1) in the azathioprine group (r2=0.57) and an increase of 23.5 ml per minute (95 percent confidence interval, 18.2 to 29.0) in the cyclophosphamide group (r2=0.56) (Figure 2Figure 2
Change in the Glomerular Filtration Rate from Study Entry to the End of the Study (18 Months) in the Azathioprine and Cyclophosphamide Groups.). End-stage renal failure developed in two patients in each group.Birmingham Vasculitis Activity Scores
The mean scores for new or worse disease decreased promptly with the initiation of remission-induction therapy (Figure 3AFigure 3
Sequential Birmingham Vasculitis Activity Score for New or Worse Disease (Panel A) and for Persistent Disease (Panel B).). The mean scores for persistent disease decreased more slowly and remained low during the trial, without significant differences between the groups (Figure 3B).Vasculitis Damage Index
At entry into the trial, most patients already had damage as a result of the disease; the mean score on the Vasculitis Damage Index was 1.3 (95 percent confidence interval, 1.0 to 1.6), reflecting at least one item indicating damage per patient. There was a significant increase in damage over the course of the trial (mean score at 18 months, 2.5 [95 percent confidence interval, 2.1 to 3.0]; P=0.003). There was no difference between the two groups in the increase in damage score during the trial.
SF-36
At entry, the mean values for measures of physical and mental health on the SF-36 were all more than 30 percent lower than the norm for the United Kingdom population, with the values for the perceived limitation on role-related activities due to physical problems more than 70 percent lower than the norm. Values for physical health measures remained substantially below the norm during the remission phase. Values for mental health measures improved and were an average of 14 percent lower than the norm at remission. The averages for the whole cohort increased significantly with time throughout the trial (P<0.001). No significant differences between groups were observed in the SF-36 score.
Inflammatory Markers
No significant differences between groups were observed in the C-reactive protein levels or the erythrocyte sedimentation rate.
Discussion
We investigated the optimal initial duration of cyclophosphamide therapy for ANCA-associated systemic vasculitis. The early substitution of azathioprine for cyclophosphamide during remission — usually at three months — resulted in a rate of relapse that was similar to that in the group receiving the control regimen of 12 months of cyclophosphamide therapy. Thus, the initial duration of exposure to cyclophosphamide and the risks of such treatment in terms of cancer and infertility can be safely reduced in patients with generalized vasculitis. The results support the concept of aggressive treatment for active disease and lower-intensity therapy for the maintenance of remission. The possible need for further cyclophosphamide treatment for late relapse adds to the importance of minimizing the initial level of exposure.
In our unblinded trial, the determination of remission and relapse by the investigator was a potential source of bias. However, the semi-objective scores for vasculitis activity and laboratory measurements of disease activity were similar in both groups at the start of the remission phase of the trial, and increases in these values at the time of relapse were also similar in both groups. The observed difference in the relapse rate was small — 1.8 percentage points — and the 95 percent confidence interval for this difference (–9.9 to 13.0 percentage points) indicates that although the real difference could be larger, it would still be less than the 20 percentage points that the study was powered to detect.
An increase in the relapse rate in the azathioprine group after 18 months cannot be ruled out, but previous longer-term experience with azathioprine suggests that any increase is unlikely to be large.21 Relapse of disease has been common after the discontinuation of therapy in patients with Wegener's granulomatosis; we are currently assessing the optimal duration of remission-maintenance therapy.18,32 The relapse rate of 15 percent was lower than that predicted on the basis of previous trials and suggests that the subgroup we studied had a lower relapse rate than other subgroups of patients with vasculitis. Similarly low rates have been reported among patients with renal vasculitis.33 The higher relapse rate among patients with Wegener's granulomatosis may reflect the additional presence of granulomatous disease and the colonization of diseased respiratory mucosa with respiratory pathogens, such as Staphylococcus aureus.32,34
We excluded patients with advanced renal failure and those whose vital-organ function was not threatened. Renal vasculitis was the most common form of organ involvement, occurring in 94 percent of the patients in our study. Induction therapy with daily oral cyclophosphamide and oral prednisolone was effective: remission was achieved in 77 percent of patients by three months and in 93 percent by six months. Patients in whom remission was not achieved had either died or been lost to follow-up, and no patient had primary treatment failure. The rate and speed of remission were greater than those reported in previous studies and may have been influenced by the exclusion of patients with severe disease and the inclusion of patients with a new diagnosis and primarily renal involvement.17,35 The good results should be balanced against the toxicity of this regimen: five of the seven deaths that occurred during the induction phase were related to treatment. Daily oral cyclophosphamide was the preferred induction therapy for this group of patients at the time the trial was designed; subsequent reports have indicated that regimens involving the intermittent, pulsed administration of cyclophosphamide are safer but are associated with a higher rate of relapse.35-38
Adverse events were frequent, and neutropenia caused by cyclophosphamide or azathioprine treatment occurred in 55 percent of the patients, despite the inclusion in the protocol of advice designed to reduce the risk of neutropenia. Because older age and renal failure predispose patients to myelosuppression, this complication is common in patients with vasculitis: the mean age of our patients was 58 years, and the mean glomerular filtration rate at entry was 49.2 ml per minute. Other cyclophosphamide-related complications, including hemorrhagic cystitis, alopecia, and amenorrhea, were rare. Hypersensitivity reactions to azathioprine led to its discontinuation in five patients, and the reactions were initially difficult to differentiate from a relapse of vasculitis. The study was not designed to detect a difference between groups in the rate of adverse events, and a reduction in the rate of late toxic effects of cyclophosphamide could not have been revealed because of the relatively short duration of the trial.
Renal outcomes were generally good, with renal failure occurring in only four patients (3 percent). There were large increases in the glomerular filtration rate, most of which occurred during the first three months. These outcomes suggest a new standard of care and highlight the importance of referral before renal failure develops, since after renal failure has occurred, outcomes are much poorer.39 Longer follow-up is required in order to determine the stability of renal recovery, particularly in patients whose renal function remains impaired.
The Birmingham Vasculitis Activity Score demonstrated sensitivity to change in parallel with laboratory measures of disease activity. The persistence of disease after induction therapy highlights a suboptimal response to treatment in a minority of patients.40 The scores on the Vasculitis Damage Index demonstrated the frequent presence of damage at presentation; such damage indicates that there is a delay between the development of symptoms and diagnosis in patients with vasculitis. The score on this index increased during the trial despite the fact that disease activity was controlled, reflecting the consequences of vasculitic inflammation and of adverse events. Further research is required to clarify the mechanisms of progressive damage, which are potential new targets of therapy. The SF-36 scores for perceived illness were extremely low at presentation, and these scores remained below normal levels at the end of the study. It is unclear whether this finding reflects a slow healing process, poor rehabilitation, vasculitic damage, subclinical disease activity, or ongoing toxic effects of the drugs.
Azathioprine was selected for use in this study because it was already widely used for the maintenance of remission in patients with renal vasculitis. Alternative therapies that merit further consideration include methotrexate, mycophenolate mofetil, leflunomide, cyclosporine, and blockade of tumor necrosis factor α.41-45 The grouping of ANCA-associated vasculitides will simplify and expedite diagnosis and the initiation of remission-induction treatment in patients with rapidly evolving vital-organ disease, although improved treatments will be required to prevent relapse. Our findings indicate that it is possible to reduce patients' exposure to cyclophosphamide and its toxic effects without increasing the rate of relapse. These findings have immediate relevance for the daily management of vasculitis.
Supported by contracts (BMH1-CT93-1078, CIPD-CT94-0307, BMH4-CT97-2328, and IC20-CT97-0019) with the European Union.
Dr. Tesar reports having received consulting or lecture fees from GlaxoSmithKline and AstraZeneca.
We are indebted to Jo Hermans and J.C. van Houwelingen (Leiden, the Netherlands) and Paul Landais (Paris) for advice on statistical analysis; to Jane Thorogood (London), the biostatistician for the trial; to Helen Talbot (Edinburgh, United Kingdom) for software design; to Fred Compton (London) for data management; and to Lucy Jayne (London), the trial administrator.
Source Information
From Addenbrooke's Hospital, Cambridge, United Kingdom (D.J.); Rigshospitalet, Copenhagen, Denmark (N.R.); the University of Heidelberg, Heidelberg, Germany (K.A.); University of Birmingham, Birmingham, United Kingdom (P.B.); the University of Maastricht, Maastricht, the Netherlands (J.W.C.T.); the University of Vilnius, Vilnius, Lithuania (J.D.); the University of Helsinki, Helsinki, Finland (A.E.); Imperial College, London (G. Gaskin, C.P.); Spedali Civili, Brescia, Italy (G. Gregorini); the Medical School, Hannover, Germany (K.G.); the Department of Rheumatology, University of Luebeck, and Rheumaklinik Bad Bramstedt, Luebeck, Germany (W.G.); Eemland Hospital, Amersfoort, the Netherlands (E.C.H.); the Hospital Clinic i Provincial, Barcelona, Spain (E.M.); the Huddinge University Hospital, Stockholm, Sweden (E.P.); the Leiden University Medical Centre, Leiden, the Netherlands (C.S.); the Ospedale San Carlo Borromeo, Milan, Italy (A.S.); the Charles University, Prague, Czech Republic (V.T.); and the University of Lund, Lund Sweden (K.W.).
Address reprint requests to Dr. Jayne at the Department of Medicine, Box 157, Addenbrooke's Hospital, Cambridge CB1 2QQ, United Kingdom.
Other investigators in the Cyclophosphamide versus Azathioprine as Remission Maintenance Therapy for ANCA-Associated Vasculitis Study are listed in the Appendix.
Appendix
In addition to the authors, the following investigators participated in the Cyclophosphamide versus Azathioprine as Remission Maintenance Therapy for ANCA-Associated Vasculitis Study. Belgium: Erasmus Hospital, Brussels — D. Abramowicz, M. Wissing; Universitaire Ziekenhuis, Leuven — D. Blockmans; Edith Cavell Medical Institute, Brussels — P. Madhoun; AZ VUB, Brussels — J. Sennesael; IMC de Tournai, Tournai — J. Stolear. Czech Republic: Charles University Hospital, Prague — V. Chabova, I. Rychlik. Finland: University of Helsinki, Helsinki — C. Grönhagen-Riska. France: Hôpital Necker, Paris — P. Lesavre; Centre Hospitalier, Valenciennes — P. Vanhille. Ireland: St. James Hospital, Dublin — C. Feighery. Germany: Heidelberg University Hospital, Heidelberg — O. Hergesell; Klinikum Mannheim, Mannheim — F. van der Woude, R. Nowack; Rheumaklinik, Bad Bramstedt — W. Schmitt; Heinrich Heine Universität, Düsseldorf — M. Schneider, C. Specker; Klinikum Nürnberg, Nürnberg — H. Rupprecht, P. Weber, S. Weidner. The Netherlands: University Hospital, Groningen — C. Kallenberg, C. Stegeman; Eemland Hospital, Amersfoort — E. van Gurp; Leiden University Medical Center, Leiden — C. Siegert, C. Verburgh. Spain: Hospital Germans Trias i Pujol, Badalona — A. Serra; Hospital Doctor Josep Trueta, Girona — M. Valles; Hospital Princeps d'España, Llobregat — R. Poveda; Fundació Puigvert, Barcelona — J. Ballarin. Sweden: Huddinge University Hospital, Huddinge — A. Bruchfeld; Danderyds Sjukhus, Danderyds — G. Germanis; University Hospital of Lund, Lund — D. Selga; Karolinska Sjukhuset, Stockholm — Z. Heigl, I. Lundberg, E. Svenungssen. United Kingdom: Southmead Hospital, Bristol — P. Mathieson; Ipswich Hospital, Ipswich — R. Watts; Leicester General Hospital, Leicester — J. Feehally; Royal Free Hospital, London — A. Burns; Western General Hospital, Edinburgh — R. Luqmani; Queen Elizabeth II Hospital, Birmingham — D. Adu, C. Savage.
- References
References
1
Jennette JC ,Falk RJ ,Andrassy K , et al. Nomenclature of systemic vasculitides: proposal of an international consensus conference. Arthritis Rheum 1994;37:187-192
CrossRef | Web of Science | Medline2
European therapeutic trials in ANCA-associated systemic vasculitis: disease scoring, consensus regimens and proposed clinical trials. Clin Exp Immunol 1995;101:Suppl 1:29-34
CrossRef | Medline3
Jennette JC ,Wilkman AS ,Falk RJ . Anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and vasculitis. Am J Pathol 1989;135:921-930
Web of Science | Medline4
Falk RJ ,Hogan S ,Carey TS ,Jennette JC . Clinical course of anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and systemic vasculitis. Ann Intern Med 1990;113:656-663
Web of Science | Medline5
Hagen EC ,Daha MR ,Hermans J , et al. Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis: EC/BCR Project for ANCA Assay Standardization. Kidney Int 1998;53:743-753
CrossRef | Web of Science | Medline6
Hogan SL ,Nachman PH ,Wilkman AS ,Jennette JC ,Falk RJ . Prognostic markers in patients wtih antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. J Am Soc Nephrol 1996;7:23-32
Web of Science | Medline7
Hauer HA ,Bajema IM ,Hermans J , et al. Analysis of 74 renal biopsies in patients with ANCA-associated vasculitis with renal involvement. Clin Exp Immunol 1998;112:Suppl 1:28-28 abstract.8
Bajema IM ,Hagen EC ,Hermans J , et al. Kidney biopsy as a predictor for renal outcome in ANCA-associated necrotizing glomerulonephritis. Kidney Int 1999;56:1751-1758
CrossRef | Web of Science | Medline9
Harper L ,Savage COS . Pathogenesis of ANCA-associated systemic vasculitis. J Pathol 2000;190:349-359
CrossRef | Web of Science | Medline10
King WJ ,Brooks CJ ,Holder R ,Hughes P ,Adu D ,Savage COS . T lymphocyte responses to anti-neutrophil cytoplasmic autoantibody (ANCA) antigens are present in patients with ANCA-associated systemic vasculitis and persist during disease remission. Clin Exp Immunol 1998;112:539-546
CrossRef | Web of Science | Medline11
Brooks CJ ,King WJ ,Radford DJ ,Adu D ,McGrath M ,Savage COS . IL-1 beta production by human polymorphonuclear leucocytes stimulated by anti-neutrophil cytoplasmic autoantibodies: relevance to systemic vasculitis. Clin Exp Immunol 1996;106:273-279
CrossRef | Web of Science | Medline12
Falk RJ ,Terrell RS ,Charles LA ,Jennette JC . Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc Natl Acad Sci U S A 1990;87:4115-4119
CrossRef | Web of Science | Medline13
Jayne D . Evidence-based treatment of systemic vasculitis. Rheumatology (Oxford) 2000;39:585-595
CrossRef | Web of Science | Medline14
Westman KW ,Bygren PG ,Olsson H ,Ranstam J ,Wieslander J . Relapse rate, renal survival, and cancer morbidity in patients with Wegener's granulomatosis or microscopic polyangiitis with renal involvement. J Am Soc Nephrol 1998;9:842-852
Web of Science | Medline15
Fauci AS ,Katz P ,Haynes BF ,Wolff SM . Cyclophosphamide therapy of severe systemic necrotizing vasculitis. N Engl J Med 1979;301:235-238
Full Text | Web of Science | Medline16
Fauci AS ,Haynes BF ,Katz P ,Wolff SM . Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med 1983;98:76-85
Web of Science | Medline17
Hoffman GS ,Kerr GS ,Leavitt RY , et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 1992;116:488-498
Web of Science | Medline18
Reinhold-Keller E ,Beuge N ,Latza U , et al. An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients. Arthritis Rheum 2000;43:1021-1032[Erratum, Arthritis Rheum 2000;43:2379.]
CrossRef | Web of Science | Medline19
Tervaert JW ,Huitema MG ,Hene RJ , et al. Prevention of relapses in Wegener's granulomatosis by treatment based on antineutrophil cytoplasmic antibody titre. Lancet 1990;336:709-711
CrossRef | Web of Science | Medline20
Jayne DR ,Gaskin G ,Pusey CD ,Lockwood CM . ANCA and predicting relapse in systemic vasculitis. QJM 1995;88:127-133
Medline21
De'Oliviera J ,Gaskin G ,Dash A ,Rees AJ ,Pusey CD . Relationship between disease activity and anti-neutrophil cytoplasmic antibody concentration in long-term management of systemic vasculitis. Am J Kidney Dis 1995;25:380-389
CrossRef | Web of Science | Medline22
Methods to detect autoantibodies to neutrophil cytoplasmic granulocytes. In: Wiik A, Rasmussen N, Wieslander J. Manual of biological markers of disease. Vol. A9. Amsterdam: Kluwer Academic, 1993:1-14.
23
Savige J ,Gillis D ,Benson E , et al. International Consensus Statement on Testing and Reporting of Antineutrophil Cytoplasmic Antibodies (ANCA). Am J Clin Pathol 1999;111:507-513
Web of Science | Medline24
Luqmani RA ,Bacon PA ,Moots RJ , et al. Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. QJM 1994;87:671-678
Medline25
Luqmani RA ,Exley AR ,Kitas GD ,Bacon PA . Disease assessment and management of the vasculitides. Baillieres Clin Rheumatol 1997;11:423-446
CrossRef | Web of Science | Medline26
Reinhold-Keller E ,Kekow J ,Schnabel A , et al. Influence of disease manifestation and antineutrophil cytoplasmic antibody titer on the response to pulse cyclophosphamide therapy in patients with Wegener's granulomatosis. Arthritis Rheum 1994;37:919-924
CrossRef | Web of Science | Medline27
Exley AR ,Bacon PA ,Luqmani RA , et al. Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. Arthritis Rheum 1997;40:371-380
CrossRef | Web of Science | Medline28
Ware JE Jr ,Sherbourne CD . The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473-483
CrossRef | Web of Science | Medline29
Jenkinson C ,Coulter A ,Wright L . Short form 36 (SF36) health survey questionnaire: normative data for adults of working age. BMJ 1993;306:1437-1440
CrossRef | Web of Science | Medline30
Bacon PA ,Moots RJ ,Exley A ,Luqmani R ,Rasmussen N . VITAL (Vasculitis Integrated Assessment Log) assessment of vasculitis. Clin Exp Rheumatol 1995;13:275-278
Web of Science | Medline31
Hauer HA ,Bajema IM ,van Houwelingen HC , et al. Renal histology in ANCA-associated vasculitis: differences between diagnostic and serologic subgroups. Kidney Int 2002;61:80-89
CrossRef | Web of Science | Medline32
Jayne DR ,Rasmussen N . Treatment of antineutrophil cytoplasm autoantibody-associated systemic vasculitis: initiatives of the European Community Systemic Vasculitis Clinical Trials Study Group. Mayo Clin Proc 1997;72:737-747
CrossRef | Web of Science | Medline33
Gaskin G ,Pusey C . Long-term outcome after immunosuppression and plasma ex-change for severe vasculitis-associated glomerulonephritis. J Am Soc Nephrol 1999;10:101A-101A abstract.34
Stegeman CA ,Tervaert JW ,Sluiter WJ ,Manson WL ,de Jong PE ,Kallenberg CG . Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosis. Ann Intern Med 1994;120:12-17
Web of Science | Medline35
Adu D ,Pall A ,Luqmani RA , et al. Controlled trial of pulse versus continuous prednisolone and cyclophosphamide in the treatment of systemic vasculitis. QJM 1997;90:401-409
CrossRef | Medline36
Guillevin L ,Cordier JF ,Lhote F , et al. A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis. Arthritis Rheum 1997;40:2187-2198
CrossRef | Web of Science | Medline37
Haubitz M ,Schellong S ,Gobel U , et al. Intravenous pulse administration of cyclophosphamide versus daily oral treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitis and renal involvement: a prospective, randomized study. Arthritis Rheum 1998;41:1835-1844
CrossRef | Web of Science | Medline38
de Groot K ,Adu D ,Savage CO . The value of pulse cyclophosphamide in ANCA-associated vasculitis: meta-analysis and critical analysis. Nephrol Dial Transplant 2001;16:2018-2027
CrossRef | Web of Science | Medline39
Pusey CD ,Rees AJ ,Evans DJ ,Peters DK ,Lockwood CM . Plasma exchange in focal necrotizing glomerulonephritis without anti-GBM antibodies. Kidney Int 1991;40:757-763
CrossRef | Web of Science | Medline40
Exley AR ,Bacon PA ,Luqmani RA ,Kitas GD ,Carruthers DM ,Moots R . Examination of disease severity in systemic vasculitis from the novel perspective of damage using the vasculitis damage index (VDI). Br J Rheumatol 1998;37:57-63
CrossRef | Medline41
Nowack R ,Gobel U ,Klooker P ,Hergesell O ,Andrassy K ,van der Woude FJ . Mycophenolate mofetil for maintenance therapy of Wegener's granulomatosis and microscopic polyangiitis: a pilot study in 11 patients with renal involvement. J Am Soc Nephrol 1999;10:1965-1971
Web of Science | Medline42
Haubitz M ,Koch KM ,Brunkhorst R . Cyclosporin for the prevention of disease reactivation in relapsing ANCA-associated vasculitis. Nephrol Dial Transplant 1998;13:2074-2076
CrossRef | Web of Science | Medline43
de Groot K ,Reinhold-Keller E ,Tatsis E , et al. Therapy for the maintenance of remission in sixty-five patients with generalized Wegener's granulomatosis: methotrexate versus trimethoprim/sulfamethoxazole. Arthritis Rheum 1996;39:2052-2061
CrossRef | Web of Science | Medline44
Szpirt WM ,Rasmussen N ,Petersen J . Plasma exchange and cyclosporin A in Wegener's granulomatosis: a controlled study. Int J Artif Organs 1996;19:501-501 abstract.45
Stone JH ,Uhlfelder ML ,Hellmann DB ,Crook S ,Bedocs NM ,Hoffman GS . Etanercept combined with conventional treatment in Wegener's granulomatosis: a six-month open-label trial to evaluate safety. Arthritis Rheum 2001;44:1149-1154
CrossRef | Web of Science | Medline
- Citing Articles (286)
Citing Articles
1
Machi Suka, Taichi Hayashi, Shigeto Kobayashi, Satoshi Ito, Wako Yumura, Shoichi Ozaki. (2012) Improvement in health-related quality of life in MPO-ANCA-associated vasculitis patients treated with cyclophosphamide plus prednisolone: an analysis of 18 months of follow-up data from the JMAAV study. Modern Rheumatology
CrossRef2
P.P. Pavlakis, H. Alexopoulos, M.L. Kosmidis, I. Mamali, H.M. Moutsopoulos, A.G. Tzioufas, M.C. Dalakas. (2012) Peripheral neuropathies in Sjögren’s syndrome: A critical update on clinical features and pathogenetic mechanisms. Journal of Autoimmunity
CrossRef3
Marinka Twilt, Susanne Benseler, David Cabral. (2012) Granulomatosis with Polyangiitis in Childhood. Current Rheumatology Reports
CrossRef4
Carol A. Langford. (2012) Update on the Treatment of Granulomatosis with Polyangiitis (Wegener’s). Current Treatment Options in Cardiovascular Medicine
CrossRef5
Ezgi Deniz Batu, Seza Ozen. (2012) Pediatric Vasculitis. Current Rheumatology Reports
CrossRef6
Philippe Vanhille, Laurence Vrigneaud, Thomas Quéméneur. (2012) Vascularites rénales associées aux ANCA. La Presse Médicale
CrossRef7
Antonio Iglesias-Gamarra, Edgar Penaranda, Luis R. Espinoza. (2011) Vasculitides Throughout History and Their Clinical Treatment Today. Current Rheumatology Reports 13:6, 465-472
CrossRef8
Tomasz Miszalski-Jamka, Wojciech Szczeklik, Barbara Sokołowska, Karol Miszalski-Jamka, Krzysztof Karwat, Gabriel Grządziel, Wojciech Mazur, Dean J. Kereiakes, Jacek Musiał. (2011) Cardiac involvement in Wegener’s granulomatosis resistant to induction therapy. European Radiology 21:11, 2297-2304
CrossRef9
P. Bacon, F. A. Wollheim. (2011) Advances in CTDs. Rheumatology 50:11, 1933-1935
CrossRef10
Marco A. Alba, Luis F. Flores-Suárez. (2011) Rituximab en el tratamiento de las vasculitis asociadas a ANCA: ¿el futuro hoy?. Reumatología Clínica
CrossRef11
Janet Dábague Guzmán, Jorge Pedroza Granados, Javier Zúñiga Varga. (2011) Tratamiento de mantenimiento en las vasculitis asociadas a anticuerpos contra citoplasma de neutrófilos (ANCA). Reumatología Clínica
CrossRef12
Rodrigo Cartin-Ceba, Fernando C. Fervenza, Ulrich Specks. (2011) Treatment of antineutrophil cytoplasmic antibody-associated vasculitis with rituximab. Current Opinion in Rheumatology1
CrossRef13
Chethana Dharmapalaiah, Richard A. Watts. (2011) The role of biologics in treatment of ANCA-associated vasculitis. Modern Rheumatology
CrossRef14
S.J. Meggitt, A.V. Anstey, M.F. Mohd Mustapa, N.J. Reynolds, S. Wakelin. (2011) British Association of Dermatologists’ guidelines for the safe and effective prescribing of azathioprine 2011. British Journal of Dermatology 165:4, 711-734
CrossRef15
Mariagrazia Catanoso, Nicolò Pipitone, Luca Magnani, Luigi Boiardi, Carlo Salvarani. (2011) New indications for biological therapies. Internal and Emergency Medicine 6:S1, 1-9
CrossRef16
Hazlita Isa, Susan Lightman, Charles D Pusey, Simon RJ Taylor. (2011) Ocular manifestations of Wegener’s granulomatosis. Expert Review of Ophthalmology 6:5, 541-555
CrossRef17
N. Mansfield, S. Hamour, A.-M. Habib, R. Tarzi, J. Levy, M. Griffith, T. Cairns, H. T. Cook, C. D. Pusey, A. D. Salama. (2011) Prolonged disease-free remission following rituximab and low-dose cyclophosphamide therapy for renal ANCA-associated vasculitis. Nephrology Dialysis Transplantation 26:10, 3280-3286
CrossRef18
Shoichi Ozaki, Tatsuya Atsumi, Taichi Hayashi, Akihiro Ishizu, Shigeto Kobayashi, Shunichi Kumagai, Yasuyuki Kurihara, Manae S. Kurokawa, Hirofumi Makino, Hiroko Nagafuchi, Kimimasa Nakabayashi, Norihiro Nishimoto, Machi Suka, Yasuhiko Tomino, Hidehiro Yamada, Kunihiro Yamagata, Masaharu Yoshida, Wako Yumura. (2011) Severity-based treatment for Japanese patients with MPO-ANCA-associated vasculitis: the JMAAV study. Modern Rheumatology
CrossRef19
M. Gavrilovski, P. Kakar, J. Rendle, E. Lawrence, K. Kee, R. Sathanathan. (2011) An unusual presentation of C-ANCA vasculitis. QJM
CrossRef20
Yoshinori Matsumoto, Ken-ei Sada, Fumio Otsuka, Mariko Takano, Noriko Toyota, Koichi Sugiyama, Hiroshi Wakabayashi, Tomoko Kawabata, Hirofumi Makino. (2011) Evaluation of weekly-reduction regimen of glucocorticoids in combination with cyclophosphamide for anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis in Japanese patients. Rheumatology International
CrossRef21
R. Suppiah, R. D. M. Hadden, R. Batra, N. K. Arden, M. P. Collins, L. Guillevin, D. R. W. Jayne, R. A. Luqmani, . (2011) Peripheral neuropathy in ANCA-associated vasculitis: outcomes from the European Vasculitis Study Group trials. Rheumatology
CrossRef22
Anmar M. Abdul-Rahman, Robert Raj. (2011) BILATERAL RETINAL BRANCH VASCULAR OCCLUSION—A FIRST PRESENTATION OF CROHN DISEASE. Retinal Cases & Brief Reports 4:2, 102-104
CrossRef23
Lavnish Joshi, Sue L. Lightman, Alan D. Salama, Amy Lee Shirodkar, Charles D. Pusey, Simon R.J. Taylor. (2011) Rituximab in Refractory Ophthalmic Wegener's Granulomatosis. Ophthalmology
CrossRef24
E. Reinhold-Keller, F. Moosig. (2011) Entwicklung von Morbidität und Mortalität bei ANCA-assoziierten Vaskulitiden. Zeitschrift für Rheumatologie 70:6, 486-492
CrossRef25
JH Takala, H Kautiainen, P Finne, M Leirisalo-Repo. (2011) Wegener's granulomatosis in Finland in 1981–2000: risk of dialysis-dependent renal disease. Scandinavian Journal of Rheumatology 40:4, 283-288
CrossRef26
L. Corral-Gudino, M. Borao-Cengotita-Bengoa, J. del Pino-Montes, J. L. Lerma-Marquez. (2011) Overall survival, renal survival and relapse in patients with microscopic polyangiitis: a systematic review of current evidence. Rheumatology 50:8, 1414-1423
CrossRef27
Matthew D. Morgan, Annette Pachnio, Jusnara Begum, David Roberts, Niels Rasmussen, Desley A. H. Neil, Ingeborg Bajema, Caroline O. S. Savage, Paul A. Moss, Lorraine Harper. (2011) CD4+CD28− T cell expansion in granulomatosis with polyangiitis (Wegener's) is driven by latent cytomegalovirus infection and is associated with an increased risk of infection and mortality. Arthritis & Rheumatism 63:7, 2127-2137
CrossRef28
Michael Walsh, Chetan Mukhtyar, Alfred Mahr, Karen Herlyn, Raashid Luqmani, Peter A. Merkel, David R. W. Jayne. (2011) Health-related quality of life in patients with newly diagnosed antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Care & Research 63:7, 1055-1061
CrossRef29
Paul A. Brogan, Jane Tizard. 2011. Wegener Granulomatosis, Polyarteritis Nodosa, Microscopic Polyangiitis, Behçet Disease and Relapsing Polychondritis. , 167.1-167.21.
CrossRef30
J. Egido, J. Rojas-Rivera, A. Barat, F. Rivera Hernández. (2011) Glomerulonefritis agudas y rápidamente progresivas. Medicine - Programa de Formación Médica Continuada Acreditado 10:82, 5532-5541
CrossRef31
E. Ntatsaki, J. Mooney, R. A. Watts. (2011) ANCA vasculitis: time for a change in treatment paradigm? Not yet. Rheumatology 50:6, 1019-1024
CrossRef32
J. Rojas-Rivera, A. Barat, J. Egido. (2011) Glomerulopatías secundarias a enfermedades sistémicas. Medicine - Programa de Formación Médica Continuada Acreditado 10:82, 5560-5580
CrossRef33
Daniel C. Cattran, Michelle A. Hladunewich. (2011) Maintenance Immunosuppression in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis. American Journal of Kidney Diseases 57:6, 818-821
CrossRef34
Marcos Martinez Del Pero, Michael Walsh, Raashid Luqmani, Oliver Flossmann, Chetan Mukhtyar, Piyush Jani, Niels Rasmussen, David Jayne. (2011) Long-term damage to the ENT system in Wegener’s granulomatosis. European Archives of Oto-Rhino-Laryngology 268:5, 733-739
CrossRef35
C. A. Langford. (2011) Cyclophosphamide as induction therapy for Wegener's granulomatosis and microscopic polyangiitis. Clinical & Experimental Immunology 164, 31-34
CrossRef36
R. Suppiah, C. Mukhtyar, O. Flossmann, F. Alberici, B. Baslund, R. Batra, D. Brown, J. Holle, Z. Hruskova, D. R. W. Jayne, A. Judge, M. A. Little, A. Palmisano, C. Stegeman, V. Tesar, A. Vaglio, K. Westman, R. Luqmani. (2011) A cross-sectional study of the Birmingham Vasculitis Activity Score version 3 in systemic vasculitis. Rheumatology 50:5, 899-905
CrossRef37
M. Haubitz. (2011) Vaskulitiden. Der Nephrologe 6:3, 249-257
CrossRef38
I. M. Bajema. (2011) Pathological classification of anti-neutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis. Clinical & Experimental Immunology 164, 14-16
CrossRef39
J. L. Merino, C. Galeano, B. Espejo, M. Rivera, M. Fernandez-Lucas, S. Caldes, M. N. Plana, M. Letosa, J. L. Teruel, C. Quereda, J. Ortuno. (2011) A retrospective study on outcome of microscopic polyangiitis in chronic renal replacement therapy. Nephrology Dialysis Transplantation 26:4, 1360-1366
CrossRef40
R. Luqmani, R. Suppiah, C. J. Edwards, R. Phillip, J. Maskell, D. Culliford, D. Jayne, K. Morishita, N. Arden. (2011) Mortality in Wegener's granulomatosis: a bimodal pattern. Rheumatology 50:4, 697-702
CrossRef41
Michael Walsh, Fausta Catapano, Wladimir Szpirt, Kristian Thorlund, Annette Bruchfeld, Loic Guillevin, Marion Haubitz, Peter A. Merkel, Chen Au Peh, Charles Pusey, David Jayne. (2011) Plasma Exchange for Renal Vasculitis and Idiopathic Rapidly Progressive Glomerulonephritis: A Meta-analysis. American Journal of Kidney Diseases 57:4, 566-574
CrossRef42
Ravi Suppiah, Andrew Judge, Rajbir Batra, Oliver Flossmann, Lorraine Harper, Peter Höglund, M. Kassim Javaid, David Jayne, Chetan Mukhtyar, Kerstin Westman, John C. Davis, Gary S. Hoffman, W. Joseph McCune, Peter A. Merkel, E. William St.Clair, Philip Seo, Robert Spiera, John H. Stone, Raashid Luqmani. (2011) A model to predict cardiovascular events in patients with newly diagnosed Wegener's granulomatosis and microscopic polyangiitis. Arthritis Care & Research 63:4, 588-596
CrossRef43
Radomir Naumovic, Dijana Jovanovic, Stevan Pavlovic, Milan Stosovic, Jelena Marinkovic, Gordana Basta-Jovanovic. (2011) Cyclosporine versus azathioprine therapy in high-risk idiopathic membranous nephropathy patients: A 3-year prospective study. Biomedicine & Pharmacotherapy 65:2, 105-110
CrossRef44
Sanjeev Baweja, Kate Wiggins, Darren Lee, Susan Blair, Margaret Fraenkel, Lawrence P. McMahon. (2011) Benefits and limitations of plasmapheresis in renal diseases: an evidence-based approach. Journal of Artificial Organs 14:1, 9-22
CrossRef45
Benjamin Wilde, Pieter van Paassen, Oliver Witzke, Jan Willem Cohen Tervaert. (2011) New pathophysiological insights and treatment of ANCA-associated vasculitis. Kidney International 79:6, 599-612
CrossRef46
J. C. Henes, L. Kanz, I. Koetter. (2011) Rituximab and leflunomide for Wegener’s granulomatosis: a long-term follow-up. Rheumatology International 31:3, 425-426
CrossRef47
W. M. Szpirt, J. G. Heaf, J. Petersen. (2011) Plasma exchange for induction and cyclosporine A for maintenance of remission in Wegener's granulomatosis--a clinical randomized controlled trial. Nephrology Dialysis Transplantation 26:1, 206-213
CrossRef48
Dario Roccatello, Savino Sciascia, Daniela Rossi, Mirella Alpa, Carla Naretto, Alessandra Russo, Elisa Menegatti, Simone Baldovino. (2011) Long-Term Effects of Rituximab Added to Cyclophosphamide in Refractory Patients with Vasculitis. American Journal of Nephrology 34:2, 175-180
CrossRef49
David Cabral, Susanne Benseler. 2011. GRANULOMATOUS VASCULITIS, MICROSCOPIC POLYANGIITIS AND PRIMARY ANGIITIS OF THE CENTRAL NERVOUS SYSTEM. , 521-543.
CrossRef50
Julia U. Holle, Wolfgang L. Gross, Ute Latza, Bernhard Nölle, Petra Ambrosch, Martin Heller, Regina Fertmann, Eva Reinhold-Keller. (2011) Improved outcome in 445 patients with Wegener's granulomatosis in a German vasculitis center over four decades. Arthritis & Rheumatism 63:1, 257-266
CrossRef51
Michael J. Dillon, Seza Ozen. 2011. POLYARTERITIS NODOSA AND CUTANEOUS POLYARTERITIS NODOSA. , 498-504.
CrossRef52
Loïc Guillevin, Christian Pagnoux, Raphaele Seror, Alfred Mahr, Luc Mouthon, Philippe Le Toumelin. (2011) The Five-Factor Score Revisited. Medicine 90:1, 19-27
CrossRef53
Rasheed A. Balogun, Emaad M. Abdel-Rahman. (2011) Therapeutic plasma exchange and renal related vasculitis: Therapeutic apheresis academy 2010. Journal of Clinical Apheresis 26:5, 291-296
CrossRef54
JCS Joint Working Group. (2011) Guideline for Management of Vasculitis Syndrome (JCS 2008). Circulation Journal 75:2, 474-503
CrossRef55
Julia U Holle, Frank Moosig, Klaus Dalhoff, Wolfgang L Gross. (2011) Conditions in subjects with rheumatic diseases: pulmonary manifestations of vasculitides. Arthritis Research & Therapy 13:3, 224
CrossRef56
Erkan Demirkaya, Raashid Luqmani, Nuray Ayaz, Abdulbaki Karaoglu, Seza Ozen, . (2011) Time to focus on outcome assessment tools for childhood vasculitis. Pediatric Rheumatology 9:1, 29
CrossRef57
Gunnar Tomasson, Maarten Boers, Michael Walsh, Michael LaValley, David Cuthbertson, Simon Carette, John C. Davis, Gary S. Hoffman, Nader A. Khalidi, Carol A. Langford, Carol A. McAlear, W. Joseph McCune, Paul A. Monach, Philip Seo, Ulrich Specks, Robert Spiera, E. William St. Clair, John H. Stone, Steven R. Ytterberg, Peter A. Merkel. (2011) Assessment of health related quality of life as an outcome measure in granulomatosis with polyangiitis (Wegener's). Arthritis Care & Researchn/a-n/a
CrossRef58
Michael Walsh, Oliver Floßmann, Annelies Berden, Kerstin Westman, Peter Höglund, Coen Stegeman, David Jayne, . (2011) Risk factors for relapse of ANCA associated vasculitis. Arthritis & Rheumatismn/a-n/a
CrossRef59
Niveditha Mohan, Gail S. Kerr. (2010) ANCA-Associated Small Vessel Vasculitis: Clinical and Therapeutic Advances. Current Rheumatology Reports 12:6, 406-413
CrossRef60
María Borao-Cengotita-Bengoa, Luis Corral-Gudino, Javier del Pino-Montes, Jose Luis Lerma-Márquez. (2010) Long-term follow-up of microscopic polyangiitis, 17-year experience at a single center. European Journal of Internal Medicine 21:6, 542-547
CrossRef61
Daigoro Hirohama, Junichi Hoshino, Eiko Hasegawa, Masayuki Yamanouchi, Noriko Hayami, Tatsuya Suwabe, Naoki Sawa, Fumi Takemoto, Yoshifumi Ubara, Shigeko Hara, Kenichi Ohashi, Kenmei Takaichi. (2010) Development of myeloperoxidase-antineutrophil cytoplasmic antibody-associated renal vasculitis in a patient receiving treatment with anti-tumor necrosis factor-α. Modern Rheumatology 20:6, 602-605
CrossRef62
C. Pierrot-Deseilligny Despujol, J. Pouchot, C. Pagnoux, J. Coste, L. Guillevin. (2010) Predictors at diagnosis of a first Wegener's granulomatosis relapse after obtaining complete remission. Rheumatology 49:11, 2181-2190
CrossRef63
Richard C. Chou, Martin C. Mihm, John H. Stone. (2010) A 44-year-old woman with right ankle pain. Arthritis Care & Research 62:11, 1665-1672
CrossRef64
Min Chen, Cees G. M. Kallenberg. (2010) ANCA-associated vasculitides—advances in pathogenesis and treatment. Nature Reviews Rheumatology 6:11, 653-664
CrossRef65
D. Stoffler, F.J. Meyer, V. Schwenger. (2010) Das pulmorenale Syndrom auf der Intensivstation. Der Pneumologe 7:6, 434-440
CrossRef66
N. J. Scolding, H. Wilson, R. Hohlfeld, C. Polman, M. I. Leite, N. E. Gilhus. 2010. Cerebral Vasculitis. , 485-489.
CrossRef67
Peter M. Villiger, Loïc Guillevin. (2010) Microscopic polyangiitis: Clinical presentation. Autoimmunity Reviews 9:12, 812-819
CrossRef68
S. Laurino, A. Chaudhry, A. Booth, G. Conte, D. Jayne. (2010) Prospective study of TNF blockade with adalimumab in ANCA-associated systemic vasculitis with renal involvement. Nephrology Dialysis Transplantation 25:10, 3307-3314
CrossRef69
Stephen K. Frankel, David Jayne. (2010) The Pulmonary Vasculitides. Clinics in Chest Medicine 31:3, 519-536
CrossRef70
Ahmad B. Tarabishy, Mark Schulte, George N. Papaliodis, Gary S. Hoffman. (2010) Wegener's Granulomatosis: Clinical Manifestations, Differential Diagnosis, and Management of Ocular and Systemic Disease. Survey of Ophthalmology 55:5, 429-444
CrossRef71
Sven Teschner, Volker Burst. (2010) Leflunomide: a drug with a potential beyond rheumatology. Immunotherapy 2:5, 637-650
CrossRef72
Chiara Baldini, Rosaria Talarico, Alessandra Della Rossa, Stefano Bombardieri. (2010) Clinical Manifestations and Treatment of Churg-Strauss Syndrome. Rheumatic Disease Clinics of North America 36:3, 527-543
CrossRef73
Richard W. Lee, David P. D'Cruz. (2010) Pulmonary renal vasculitis syndromes. Autoimmunity Reviews 9:10, 657-660
CrossRef74
Michael Walsh, Peter A. Merkel, Alfred Mahr, David Jayne. (2010) Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody-associated vasculitis: A meta-analysis. Arthritis Care & Research 62:8, 1166-1173
CrossRef75
Joannis Vamvakopoulos, Caroline O. Savage, Lorraine Harper. (2010) ANCA-associated vasculitides—lessons from the adult literature. Pediatric Nephrology 25:8, 1397-1407
CrossRef76
Julia U. Holle, Martin Laudien, Wolfgang L. Gross. (2010) Clinical Manifestations and Treatment of Wegener's Granulomatosis. Rheumatic Disease Clinics of North America 36:3, 507-526
CrossRef77
David E Leaf, Gerald B Appel, Jai Radhakrishnan. (2010) Glomerular disease: why is there a dearth of high quality clinical trials?. Kidney International 78:4, 337-342
CrossRef78
Angelo L. Gaffo. (2010) Diagnostic Approach to ANCA-associated Vasculitides. Rheumatic Disease Clinics of North America 36:3, 491-506
CrossRef79
Ravi Suppiah, Joanna Robson, Raashid Luqmani. (2010) Outcome Measures in ANCA-associated Vasculitis. Rheumatic Disease Clinics of North America 36:3, 587-607
CrossRef80
Abraham Rutgers, Jan S.F. Sanders, Coen A. Stegeman, Cees G.M. Kallenberg. (2010) Pauci-Immune Necrotizing Glomerulonephritis. Rheumatic Disease Clinics of North America 36:3, 559-572
CrossRef81
Jones, Rachel B., Cohen Tervaert, Jan Willem, Hauser, Thomas, Luqmani, Raashid, Morgan, Matthew D., Peh, Chen Au, Savage, Caroline O., Segelmark, Mårten, Tesar, Vladimir, van Paassen, Pieter, Walsh, Dorothy, Walsh, Michael, Westman, Kerstin, Jayne, David R.W., . (2010) Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis. New England Journal of Medicine 363:3, 211-220
Full Text82
Falk, Ronald J., Jennette, J. Charles, . (2010) Rituximab in ANCA-Associated Disease. New England Journal of Medicine 363:3, 285-286
Full Text83
Stone, John H., Merkel, Peter A., Spiera, Robert, Seo, Philip, Langford, Carol A., Hoffman, Gary S., Kallenberg, Cees G.M., St. Clair, E. William, Turkiewicz, Anthony, Tchao, Nadia K., Webber, Lisa, Ding, Linna, Sejismundo, Lourdes P., Mieras, Kathleen, Weitzenkamp, David, Ikle, David, Seyfert-Margolis, Vicki, Mueller, Mark, Brunetta, Paul, Allen, Nancy B., Fervenza, Fernando C., Geetha, Duvuru, Keogh, Karina A., Kissin, Eugene Y., Monach, Paul A., Peikert, Tobias, Stegeman, Coen, Ytterberg, Steven R., Specks, Ulrich, . (2010) Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis. New England Journal of Medicine 363:3, 221-232
Full Text84
Justin C. Mason. (2010) Takayasu arteritis—advances in diagnosis and management. Nature Reviews Rheumatology 6:7, 406-415
CrossRef85
Paul Brogan, Despina Eleftheriou, Michael Dillon. (2010) Small vessel vasculitis. Pediatric Nephrology 25:6, 1025-1035
CrossRef86
MATT HALL, NIGEL J BRUNSKILL. (2010) GLOMERULONEPHRITIS AND THE NEPHROTIC SYNDROME IN PREGNANCY. Fetal and Maternal Medicine Review 21:02, 163-184
CrossRef87
A. Miller, M. Chan, A. Wiik, S. A. Misbah, R. A. Luqmani. (2010) An approach to the diagnosis and management of systemic vasculitis. Clinical & Experimental Immunology 160:2, 143-160
CrossRef88
Mi Yeon Kim, Sun Youn Bae, Mirae Lee, Hojung Chung, Jaejoon Lee, Joong Kyong Ahn, Hoon-Suk Cha, Eun-Mi Koh. (2010) A case of ANCA-associated vasculitis presenting with calf claudication. Rheumatology International
CrossRef89
P. Imbach, A. H. Lazarus, T. Kühne. (2010) Intravenous immunoglobulins induce potentially synergistic immunomodulations in autoimmune disorders. Vox Sanguinis 98:3p2, 385-394
CrossRef90
Marinopoulos, Spyridon S., Coylewright, Megan, Auwaerter, Paul G., Flynn, John A., . (2010) More Than Meets the Ear. New England Journal of Medicine 362:13, 1228-1233
Full Text91
Julia D Flint, Caroline OS Savage. 2010. Immune Vasculitis. .
CrossRef92
O. Flossmann, D. R. W. Jayne. (2010) Long-term treatment of relapsing Wegener's granulomatosis with 15-deoxyspergualin. Rheumatology 49:3, 556-562
CrossRef93
Richard A. Watts. (2010) Vasculitis syndromes: Inducing remission in ANCA-positive vasculitis: time to RAVE?. Nature Reviews Rheumatology 6:3, 127-128
CrossRef94
Elspeth J Hutton, Michael PT Lunn. (2010) Treatment in inflammatory neuropathies. Expert Review of Clinical Immunology 6:2, 231-245
CrossRef95
Lisa S Jeffs, Plinio R Hurtado, Randall J Faull, Chen Au Peh. (2010) Antineutrophil cytoplasmic antibody-associated vasculitis with renal involvement: the evidence for treatment. International Journal of Evidence-Based Healthcare 8:1, 18-27
CrossRef96
Matthew D. Morgan, Charles J. Ferro, Lorraine Harper. (2010) An increased risk of ischemic heart disease in Wegener's granulomatosis: Comment on the article by Faurschou et al. Arthritis & Rheumatism 62:2, 637-638
CrossRef97
Clara J. Day, Alec J. Howie, Peter Nightingale, Shazia Shabir, Dwomoa Adu, Caroline O. Savage, Peter Hewins. (2010) Prediction of ESRD in Pauci-immune Necrotizing Glomerulonephritis: Quantitative Histomorphometric Assessment and Serum Creatinine. American Journal of Kidney Diseases 55:2, 250-258
CrossRef98
Yusuke Suzuki, Yukihiko Takeda, Daisuke Sato, Yasuhiko Kanaguchi, Yuichi Tanaka, Shigeto Kobayashi, Kazuo Suzuki, Hiroshi Hashimoto, Shoichi Ozaki, Satoshi Horikoshi, Yasuhiko Tomino. (2010) Clinicoepidemiological manifestations of RPGN and ANCA-associated vasculitides: an 11-year retrospective hospital-based study in Japan. Modern Rheumatology 20:1, 54-62
CrossRef99
Les Barnsley, Rachelle Buchbinder, Sean Riminton, Les Barnsley. 2010. Anti-cytokine therapies for primary systemic necrotizing vasculitis. .
CrossRef100
Johan Bratt. 2010. Management of Medium and Small Vessel Vasculitis, Including the Antineutrophil Cytoplasmic Antibody–Associated Diseases. , 206-222.
CrossRef101
Yoshiro HORAI, Tomoya MIYAMURA, Soichiro TAKAHAMA, Akie HIRATA, Masataka NAKAMURA, Hitoshi ANDO, Rumi MINAMI, Masahiro YAMAMOTO, Eiichi SUEMATSU. (2010) Refractory antineutrophil cytoplasmic antibody-associated vasculitis successfully treated with rituximab : A case report.. Japanese Journal of Clinical Immunology 33:2, 105-110
CrossRef102
Christian Pagnoux, Loïc Guillevin. (2010) Churg–Strauss syndrome: evidence for disease subtypes?. Current Opinion in Rheumatology 22:1, 21-28
CrossRef103
Andrew S. Wilson, Paul A. Bacon, Stephen P. Young, David M. Carruthers. (2010) Vasculitis Integrated Clinical Assessment Database. JCR: Journal of Clinical Rheumatology 16:1, 10-14
CrossRef104
Wan-sik Uhm. (2010) ANCA Associated Vasculitis. The Journal of the Korean Rheumatism Association 17:2, 108
CrossRef105
Paul A. Monach, Lindsay M. Arnold, Peter A. Merkel. (2010) Incidence and prevention of bladder toxicity from cyclophosphamide in the treatment of rheumatic diseases: A data-driven review. Arthritis & Rheumatism 62:1, 9-21
CrossRef106
Lorraine Harper. (2010) Recent advances to achieve remission induction in antineutrophil cytoplasmic antibody-associated vasculitis. Current Opinion in Rheumatology 22:1, 37-42
CrossRef107
Iñigo Rúa-Figueroa Fernández de Larrinoa, Celia Erausquin Arruabarrena. (2010) Treatment of ANCA-associated systemic vasculitis. Reumatolog ía Cl ínica (English Edition) 6:3, 161-172
CrossRef108
, Akio Koyama, Kunihiro Yamagata, Hirofumi Makino, Yoshihiro Arimura, Takashi Wada, Kosaku Nitta, Hiroshi Nihei, Eri Muso, Yoshio Taguma, Hidekazu Shigematsu, Hideto Sakai, Yasuhiko Tomino, Seiichi Matsuo. (2009) A nationwide survey of rapidly progressive glomerulonephritis in Japan: etiology, prognosis and treatment diversity. Clinical and Experimental Nephrology 13:6, 633-650
CrossRef109
Vijay R. Karia, Luis R. Espinoza. (2009) Risk factors for treatment failures in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis. Current Rheumatology Reports 11:6, 416-421
CrossRef110
Chih-Chiang Wang, Jeng-Chuan Shiang, Ming-Kai Tsai, I-Hung Chen, Shih-Hua Lin, Pauling Chu, Chia-Chao Wu. (2009) Prompt plasmapheresis successfully rescue pulmonary-renal syndrome caused by ANCA-negative microscopic polyangiitis. Clinical Rheumatology 28:12, 1457-1460
CrossRef111
Christian Pagnoux, Michelle Goulet. (2009) Role and place of methotrexate in vasculitis management. International Journal of Clinical Rheumatology 4:6, 697-715
CrossRef112
A. J. Mohammad, L. T. H. Jacobsson, K. W. A. Westman, G. Sturfelt, M. Segelmark. (2009) Incidence and survival rates in Wegener's granulomatosis, microscopic polyangiitis, Churg-Strauss syndrome and polyarteritis nodosa. Rheumatology 48:12, 1560-1565
CrossRef113
Marina N. Magrey, Alexandra Villa-Forte, Curry L. Koening, Jonathan L. Myles, Gary S. Hoffman. (2009) Persistent Hematuria After Induction of Remission in Wegener Granulomatosis. Medicine 88:6, 315-321
CrossRef114
A. Schreiber, U. Göbel, R. Kettritz. (2009) ANCA-assoziierte Vaskulitis. Der Nephrologe 4:6, 541-553
CrossRef115
Patricia Carrilho, Pedro Cruz, Ana Natario, Carla Rocha, Jose Assuncao, Carlos Barreto, Alvaro Vaz, Ana Paula Martins, Jose Vinhas. (2009) Churg-Strauss and Goodpasture's syndromes: A rare association. Dialysis & Transplantation 38:11, 470-471
CrossRef116
Neil J. Scolding. (2009) Central nervous system vasculitis. Seminars in Immunopathology 31:4, 527-536
CrossRef117
Serpil Muge Deger, Ruya Mutluay, Fatma Ayerden Ebinc, Turgay Arinsoy, Sukru Sindel. (2009) Renal cell carcinoma associated immunosuppressive therapy: a case report with Wegener’s granulomatosis. Rheumatology International 30:1, 119-121
CrossRef118
D. Eleftheriou, M. Melo, S. D. Marks, K. Tullus, J. Sills, G. Cleary, P. Dolezalova, S. Ozen, C. Pilkington, P. Woo, N. Klein, M. J. Dillon, P. A. Brogan. (2009) Biologic therapy in primary systemic vasculitis of the young. Rheumatology 48:8, 978-986
CrossRef119
M. Martinez Del Pero, A. Chaudhry, R.B. Jones, P. Sivasothy, P. Jani, D. Jayne. (2009) B-cell depletion with rituximab for refractory head and neck Wegener’s granulomatosis: a cohort study. Clinical Otolaryngology 34:4, 328-335
CrossRef120
Patricia M Fortin, Aaron M Tejani, Ken Bassett, Vijaya M Musini, Patricia M Fortin. 2009. Intravenous immunoglobulin as adjuvant therapy for Wegener's granulomatosis. .
CrossRef121
Renato A. Sinico, Paolo Bottero. (2009) Churg–Strauss angiitis. Best Practice & Research Clinical Rheumatology 23:3, 355-366
CrossRef122
L. Guillevin. (2009) Vasculopathy and pulmonary arterial hypertension. Rheumatology 48:Supplement 3, iii54-iii57
CrossRef123
Chetan Mukhtyar, Paul Brogan, Raashid Luqmani. (2009) Cardiovascular involvement in primary systemic vasculitis. Best Practice & Research Clinical Rheumatology 23:3, 419-428
CrossRef124
Despina Eleftheriou, Paul A. Brogan. (2009) Vasculitis in children. Best Practice & Research Clinical Rheumatology 23:3, 309-323
CrossRef125
Thomas F. Hiemstra, David Jayne. (2009) Newer therapies for vasculitis. Best Practice & Research Clinical Rheumatology 23:3, 379-389
CrossRef126
Atul Khasnis, Carol A. Langford. (2009) Update on vasculitis. Journal of Allergy and Clinical Immunology 123:6, 1226-1236
CrossRef127
Richard A. Watts, David G.I. Scott. (2009) Recent developments in the classification and assessment of vasculitis. Best Practice & Research Clinical Rheumatology 23:3, 429-443
CrossRef128
E. Reinhold-Keller, K. Warnatz. (2009) Cyclophosphamid oral vs. Bolus bei Wegener-Granulomatose und anderen ANCA-assoziierten Vaskulitiden. Zeitschrift für Rheumatologie 68:4, 345-348
CrossRef129
Jennifer Turnbull, Lorraine Harper. (2009) Adverse effects of therapy for ANCA-associated vasculitis. Best Practice & Research Clinical Rheumatology 23:3, 391-401
CrossRef130
David Jayne. (2009) The diagnosis of vasculitis. Best Practice & Research Clinical Rheumatology 23:3, 445-453
CrossRef131
David Carruthers, Jonathan Sherlock. (2009) Evidence-based management of ANCA vasculitis. Best Practice & Research Clinical Rheumatology 23:3, 367-378
CrossRef132
Lalit Pallan, Caroline O. Savage, Lorraine Harper. (2009) ANCA-associated vasculitis: from bench research to novel treatments. Nature Reviews Nephrology 5:5, 278-286
CrossRef133
J.U. Holle, W.L. Gross. (2009) ANCA-associated vasculitides: Pathogenetic aspects and current evidence-based therapy. Journal of Autoimmunity 32:3-4, 163-171
CrossRef134
Patrick H. Nachman. (2009) Vasculitis Syndromes: Which maintenance therapy for ANCA vasculitis?. Nature Reviews Nephrology 5:5, 254-256
CrossRef135
Richard Watts. (2009) Vasculitis syndromes: Vasculitis therapy—between Scylla and Charybdis. Nature Reviews Rheumatology 5:4, 183-184
CrossRef136
R. Nowack, P. Wachtler, J. Kunz, N. Rasmussen. (2009) Cranial nerve palsy in Wegener’s granulomatosis – Lessons from clinical cases. Journal of Neurology 256:3, 299-304
CrossRef137
F. Moosig, J.U. Holle, W.L. Gross. (2009) Autoimmunvaskulitiden. Der Internist 50:3, 298-309
CrossRef138
Delesha M. Carpenter, Carolyn T. Thorpe, Megan Lewis, Robert F. Devellis, Susan L. Hogan. (2009) Health-related quality of life for patients with vasculitis and their spouses. Arthritis & Rheumatism 61:2, 259-265
CrossRef139
K. Groot, E. Reinhold-Keller. (2009) Wegener-Granulomatose und mikroskopische Polyangiitis. Zeitschrift für Rheumatologie 68:1, 49-64
CrossRef140
DAVID JAYNE. (2009) Review article: Progress of treatment in ANCA-associated vasculitis. Nephrology 14:1, 42-48
CrossRef141
Roy M. Fleischmann. (2009) Safety of Biologic Therapy in Rheumatoid Arthritis and Other Autoimmune Diseases: Focus on Rituximab. Seminars in Arthritis and Rheumatism 38:4, 265-280
CrossRef142
P.M. Aries, A. Gause. (2009) Vaskulitis. Zeitschrift für Rheumatologie 68:1, 44-48
CrossRef143
M. Faurschou, L. Mellemkjaer, I. J. Sorensen, B. S. Thomsen, L. Dreyer, B. Baslund. (2009) Cancer preceding Wegener's granulomatosis: a case-control study. Rheumatology 48:4, 421-424
CrossRef144
Yoshiro HORAI, Tomoya MIYAMURA, Soichiro TAKAHAMA, Koshiro SONOMOTO, Masataka NAKAMURA, Hitoshi ANDO, Rumi MINAMI, Masahiro YAMAMOTO, Eiichi SUEMATSU. (2009) Microscopic polyangiitis in a patient on hemodialysis : A case report.. Japanese Journal of Clinical Immunology 32:6, 506-510
CrossRef145
Akiko Iwasawa, Noriko Ikegaya, Masaki Saitou, Shinya Kaname, Yoshihiro Arimura, Akira Yamada, Masaru Ogawa. (2009) A case report of a maintenance hemodialysis patient who relapsed with alveolar hemorrhaging after a high MPO-ANCA titer that persisted for 18 years. Nihon Toseki Igakkai Zasshi 42:10, 777-783
CrossRef146
Pagnoux, Christian, Mahr, Alfred, Hamidou, Mohamed A., Boffa, Jean-Jacques, Ruivard, Marc, Ducroix, Jean-Pierre, Kyndt, Xavier, Lifermann, François, Papo, Thomas, Lambert, Marc, Le Noach, José, Khellaf, Mehdi, Merrien, Dominique, Puéchal, Xavier, Vinzio, Stéphane, Cohen, Pascal, Mouthon, Luc, Cordier, Jean-François, Guillevin, Loïc, . (2008) Azathioprine or Methotrexate Maintenance for ANCA-Associated Vasculitis. New England Journal of Medicine 359:26, 2790-2803
Full Text147
Anne Miller, Neil Basu, Raashid Luqmani. (2008) Assessment of systemic vasculitis. Autoimmunity Reviews 8:2, 170-175
CrossRef148
A.I. Kälsch, R. Birck. (2008) ANCA-assoziierte Vaskulitiden. Der Nephrologe 3:6, 476-483
CrossRef149
Jean-Emmanuel Kahn, Olivier Blétry, Loïc Guillevin. (2008) Hypereosinophilic syndromes. Best Practice & Research Clinical Rheumatology 22:5, 863-882
CrossRef150
Loïc Guillevin. (2008) Advances in the Treatments of Systemic Vasculitides. Clinical Reviews in Allergy & Immunology 35:1-2, 72-78
CrossRef151
Aarat M. Patel, Thomas J. A. Lehman. (2008) Rituximab for Severe Refractory Pediatric Wegener Granulomatosis. JCR: Journal of Clinical Rheumatology 14:5, 278-280
CrossRef152
Asha J Chemmalakuzhy, Xin J Zhou, S Susan Hedayati. (2008) ANCA-negative glomerulonephritis associated with nonasthmatic Churg–Strauss syndrome. Nature Clinical Practice Nephrology 4:10, 568-574
CrossRef153
Kan Saiga, Minako Yoshida, Iwao Nakamura, Eriko Toyoda, Kazuhiro Tokunaka, Hirohisa Morohashi, Fuminori Abe, Kyuichi Nemoto, Masato Nose. (2008) Evaluation of the ameliorative effects of immunosuppressants on crescentic glomerulonephritis in SCG/Kj mice. International Immunopharmacology 8:9, 1183-1189
CrossRef154
Oliver Flossmann, David RW Jayne. (2008) Maintaining remission in a patient with vasculitis. Nature Clinical Practice Rheumatology 4:9, 499-504
CrossRef155
Solomon Menahem, Balaji Hiremagalur, David Mudge, Nigel Toussaint, Giles Walters. (2008) Induction and maintenance therapy in ANCA-associated systemic vasculitis. Nephrology 13, S24-S36
CrossRef156
Kensuke Joh, Eri Muso, Hidekazu Shigematsu, Masato Nose, Michio Nagata, Yoshihiro Arimura, Wako Yumura, Takashi Wada, Kousaku Nitta, Hirofumi Makino, Yoshio Taguma, Hidetoshi Kaneoka, Yuhsuke Suzuki, Masaki Kobayashi, Akio Koyama, Joichi Usui, Hiroshi Hashimoto, Shoichi Ozaki, Yasuhiko Tomino, Kunihiro Yamagata. (2008) Renal pathology of ANCA-related vasculitis: proposal for standardization of pathological diagnosis in Japan. Clinical and Experimental Nephrology 12:4, 277-291
CrossRef157
Giles Walters, Narelle S Willis, Jonathan C Craig, Giles Walters. 2008. Interventions for renal vasculitis in adults. .
CrossRef158
R Manna, G Cadoni, E Ferri, E Verrecchia, M Giovinale, C Fonnesu, L Calò, E Armato, G Paludetti. (2008) Wegener’s granulomatosis: an update on diagnosis and therapy. Expert Review of Clinical Immunology 4:4, 481-495
CrossRef159
P. Renzulli, I. Winiger, R. Weimann, P. Berg, M. Gugger, D. Candinas. (2008) Husten, Rhinitis, Fieber, hämorrhagischer Schock. Der Pneumologe 5:4, 252-258
CrossRef160
Laurence H. Beck, David J. Salant. (2008) Glomerular and Tubulointerstitial Diseases. Primary Care: Clinics in Office Practice 35:2, 265-296
CrossRef161
Claas H. Hinze, Robert A. Colbert. (2008) B-Cell Depletion in Wegener’s Granulomatosis. Clinical Reviews in Allergy & Immunology 34:3, 372-379
CrossRef162
Eamonn S Molloy, Carol A Langford. (2008) Balancing efficacy and cancer risk of cyclophosphamide for patients with Wegener's granulomatosis. Nature Clinical Practice Rheumatology
CrossRef163
Justin M. Bachmann, Noel A. Brownlee, Joshua T. Schiffer. (2008) Multisystem Mystery. The American Journal of Medicine 121:5, 387-389
CrossRef164
C. Sunderkötter, K. Groot. (2008) Therapie von Vaskulitiden und Vaskulopathien. Der Hautarzt 59:5, 382-393
CrossRef165
Patricia M Fortin, Aaron Tejani, Ken Bassett, Vijaya M Musini, Patricia M Fortin. 2008. Intravenous immunoglobulin for Wegener's granulomatosis. .
CrossRef166
Christopher F. Wong. (2008) Rituximab and Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. JCR: Journal of Clinical Rheumatology 14:2, 61-64
CrossRef167
Deana D. Hoganson, Aaron M. From, Clement J. Michet. (2008) ANCA Vasculitis in the Elderly. JCR: Journal of Clinical Rheumatology 14:2, 78-81
CrossRef168
Achille Aouba, Christian Pagnoux, Boris Bienvenu, Alfred Mahr, Loïc Guillevin. (2008) Analysis of Wegener’s Granulomatosis Responses to Rituximab: Current Evidence and Therapeutic Prospects. Clinical Reviews in Allergy & Immunology 34:1, 65-73
CrossRef169
David J Salant. (2008) Intravenous methylprednisolone or plasma exchange for adjunctive therapy of severe renal vasculitis?. Nature Clinical Practice Nephrology 4:1, 14-15
CrossRef170
Alice Sue Appel, Gerald B. Appel. 2008. Immunosuppressive Agents for the Therapy of Glomerular and Tubulointerstitial Disease. , 105-111.
CrossRef171
Jeremy B. Levy, Charles D. Pusey. 2008. Systemic Vasculitis and Pauci-Immune Glomerulonephritis. , 187-196.
CrossRef172
David Jayne. 2008. Plasmapheresis in Renal Diseases. , 125-139.
CrossRef173
Valérie Martinez, Pascal Cohen, Christian Pagnoux, Stéphane Vinzio, Alfred Mahr, Luc Mouthon, Laurent Sailler, Claire Delaunay, Alain Sadoun, Loïc Guillevin, . (2008) Intravenous immunoglobulins for relapses of systemic vasculitides associated with antineutrophil cytoplasmic autoantibodies: Results of a multicenter, prospective, open-label study of twenty-two patients. Arthritis & Rheumatism 58:1, 308-317
CrossRef174
Doubravka Frausova, Martina Brejnikova, Zdenka Hruskova, Zuzana Rihova, Vladimir Tesar. (2008) Outcome of Thirty Patients with ANCA-Associated Renal Vasculitis Admitted to the Intensive Care Unit. Renal Failure 30:9, 890-895
CrossRef175
David Jayne. (2008) Challenges in the management of microscopic polyangiitis: past, present and future. Current Opinion in Rheumatology 20:1, 3-9
CrossRef176
John H. Stone, David B. Hellmann. 2008. Small- and medium-vessel primary vasculitis. , 859-883.
CrossRef177
Ching M Cheung, Arvind Ponnusamy, John G Anderton. (2008) Management of Acute Renal Failure in the Elderly Patient. Drugs & Aging 25:6, 455-476
CrossRef178
M. W. Cullen, C. C. Kennedy, U. Specks. (2008) 55-Year-Old Man With Purpura and Foot Pain. Mayo Clinic Proceedings 83:1, 93-96
CrossRef179
Philip Seo, John H. Stone. (2007) Small-vessel and medium-vessel vasculitis. Arthritis & Rheumatism 57:8, 1552-1559
CrossRef180
L. Guillevin. (2007) Vingt-sept ans d’activités du groupe français d’étude des vascularites (GFEV). La Revue de Médecine Interne 28, S263-S265
CrossRef181
C. Pagnoux. (2007) Maladie de Wegener. La Revue de Médecine Interne 28, S261-S262
CrossRef182
Chetan Mukhtyar, Antoni Chan, Raashid Luqmani. (2007) Update on the use of biologics in primary systemic vasculitides. Expert Review of Clinical Immunology 3:6, 901-911
CrossRef183
Jason M. Golbin, Ulrich Specks. (2007) Targeting B Lymphocytes as Therapy for ANCA-Associated Vasculitis. Rheumatic Disease Clinics of North America 33:4, 741-754
CrossRef184
John H. Stone. (2007) Vasculitis: A Collection of Pearls and Myths. Rheumatic Disease Clinics of North America 33:4, 691-739
CrossRef185
Chi Chiu Mok. (2007) Management of systemic lupus erythematosus in Chinese patients. Expert Review of Clinical Immunology 3:6, 925-935
CrossRef186
Sofia Lionaki, J. Charles Jennette, Ronald J. Falk. (2007) Anti-neutrophil cytoplasmic (ANCA) and anti-glomerular basement membrane (GBM) autoantibodies in necrotizing and crescentic glomerulonephritis. Seminars in Immunopathology 29:4, 459-474
CrossRef187
Xavier Puéchal. (2007) Antineutrophil cytoplasmic antibody-associated vasculitides. Joint Bone Spine 74:5, 427-435
CrossRef188
Alexandra Villa-Forte, Tiffany M. Clark, Marcelo Gomes, John Carey, Edward Mascha, Matthew T. Karafa, Gerald Roberson, Carol A. Langford, Gary S. Hoffman. (2007) Substitution of Methotrexate for Cyclophosphamide in Wegener Granulomatosis. Medicine 86:5, 269-277
CrossRef189
Sibylle von Vietinghoff, Mira Choi, Susanne Rolle, Friedrich C. Luft, Ralph Kettritz. (2007) Febrile temperatures control antineutrophil cytoplasmic autoantibody–induced neutrophil activation via inhibition of phosphatidylinositol 3-kinase/Akt. Arthritis & Rheumatism 56:9, 3149-3158
CrossRef190
Rosalind Foster, David P D'Cruz. (2007) Vasculitis in pregnancy. Expert Review of Obstetrics & Gynecology 2:5, 681-688
CrossRef191
Carol A. Langford. (2007) Small-vessel vasculitis: Therapeutic management. Current Rheumatology Reports 9:4, 328-335
CrossRef192
Anjali Nataraja, Chetan Mukhtyar, Bernhard Hellmich, Carol Langford, Raashid Luqmani. (2007) Outpatient assessment of systemic vasculitis. Best Practice & Research Clinical Rheumatology 21:4, 713-732
CrossRef193
Frauke Weidanz, Clara J. Day, Peter Hewins, Caroline O. Savage, Lorraine Harper. (2007) Recurrences and Infections During Continuous Immunosuppressive Therapy After Beginning Dialysis in ANCA-Associated Vasculitis. American Journal of Kidney Diseases 50:1, 36-46
CrossRef194
Melissa Wise, Jeffrey P Callen. (2007) Azathioprine: a guide for the management of dermatology patients. Dermatologic Therapy 20:4, 206-215
CrossRef195
Pascal Cohen, Christian Pagnoux, Alfred Mahr, Jean-Pierre Arène, Luc Mouthon, Véronique Le Guern, Marie-Hélène André, Martine Gayraud, David Jayne, Daniel Blöckmans, Jean-franÇois Cordier, Loïc Guillevin, . (2007) Churg-Strauss syndrome with poor-prognosis factors: A prospective multicenter trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in forty-eight patients. Arthritis & Rheumatism 57:4, 686-693
CrossRef196
A. Carreño Parrilla, F. Rivera Hernández. (2007) Glomerulonefritis agudas y rápidamente progresivas. Medicine - Programa de Formación Médica Continuada Acreditado 9:80, 5131-5138
CrossRef197
Oliver Flossmann, Kirsten de Groot. (2007) When should patients with ANCA-associated vasculitis be switched from induction to maintenance therapy?. Nature Clinical Practice Nephrology 3:5, 236-237
CrossRef198
Umut Selamet, Yuriy B Kovaliv, Caroline O Savage, Lorraine Harper. (2007) ANCA-associated vasculitis: new options beyond steroids and cytotoxic drugs. Expert Opinion on Investigational Drugs 16:5, 689-703
CrossRef199
Ronald J Falk, Gary S Hoffman. (2007) Controversies in small vessel vasculitis – comparing the rheumatology and nephrology views. Current Opinion in Internal Medicine 6:2, 201-209
CrossRef200
Ted M. Burns, Gregory A. Schaublin, P. James B. Dyck. (2007) Vasculitic Neuropathies. Neurologic Clinics 25:1, 89-113
CrossRef201
Carol A. Langford. (2007) Vasculitis in the Geriatric Population. Rheumatic Disease Clinics of North America 33:1, 177-195
CrossRef202
Simon R J Taylor, Alan D Salama, Charles D Pusey, Susan Lightman. (2007) Ocular manifestations of Wegener’s granulomatosis. Expert Review of Ophthalmology 2:1, 91-103
CrossRef203
Alexander FJE Vrancken, Richard AC Hughes, Gérard Said, John HJ Wokke, Nicolette C Notermans, Alexander FJE Vrancken. 2007. Immunosuppressive treatment for non-systemic vasculitic neuropathy. .
CrossRef204
Shoichi Ozaki. (2007) ANCA-associated Vasculitis: Diagnostic and Therapeutic Strategy. Allergology International 56:2, 87-96
CrossRef205
Loïc Guillevin, Christian Pagnoux. (2007) Therapeutic Strategies for Systemic Necrotizing Vasculitides. Allergology International 56:2, 105-111
CrossRef206
Shigehiro Uezono, Yuji Sato, Seiichiro Hara, Shuichi Hisanaga, Keiichi Fukudome, Shouichi Fujimoto, Hiroyuki Nakao, Kazuo Kitamura, Shigeto Kobayashi, Kazuo Suzuki, Hiroshi Hashimoto, Hiroyuki Nunoi. (2007) Outcome of ANCA-Associated Primary Renal Vasculitis in Miyazaki Prefecture. Internal Medicine 46:12, 815-822
CrossRef207
Alberto Pesci, Paolo Manganelli. (2007) Respiratory System Involvement??in Antineutrophil??Cytoplasmic-Associated Systemic Vasculitides. Drugs in R & D 8:1, 25-42
CrossRef208
Russell E. Bartt, Jordan L. Topel. 2007. Autoimmune and Inflammatory Disorders. , 1155-1184.
CrossRef209
Kenneth C. Gorson. (2007) Vasculitic Neuropathies. The Neurologist 13:1, 12-19
CrossRef210
Tomoki ORIGUCHI, Kunihiro ICHINOSE, Mami TAMAI, Hideki NAKAMURA, Atsushi KAWAKAMI, Katsumi EGUCHI. (2007) Progress in pathogenesis and therapy of vasculitis syndrome. Japanese Journal of Clinical Immunology 30:6, 432-443
CrossRef211
Naoto Tamura, Ran Matsudaira, Mika Hirashima, Makoto Ikeda, Michiko Tajima, Masuyuki Nawata, Shinji Morimoto, Kazuhiko Kaneda, Shigeto Kobayashi, Hiroshi Hashimoto, Yoshinari Takasaki. (2007) Two Cases of Refractory Wegeners Granulomatosis Successfully Treated with Rituximab. Internal Medicine 46:7, 409-414
CrossRef212
M. Pechula Thut, T. Hauser. (2007) Rasch-progrediente Glomerulonephritis. Der Nephrologe 2:1, 27-32
CrossRef213
Cees GM Kallenberg. (2007) Antineutrophil cytoplasmic autoantibody-associated small-vessel vasculitis. Current Opinion in Rheumatology 19:1, 17-24
CrossRef214
Masami Taniguchi, Naomi Tsurikisawa, Noritaka Higashi, Hiroshi Saito, Haruhisa Mita, Akio Mori, Hiroki Sakakibara, Kazuo Akiyama. (2007) Treatment for Churg-Strauss Syndrome: Induction of Remission and Efficacy of Intravenous Immunoglobulin Therapy. Allergology International 56:2, 97-103
CrossRef215
Christian Pagnoux, Philippe Guilpain, Loïc Guillevin. (2007) Churg–Strauss syndrome. Current Opinion in Rheumatology 19:1, 25-32
CrossRef216
Cees GM Kallenberg, Peter Heeringa, Coen A Stegeman. (2006) Mechanisms of Disease: pathogenesis and treatment of ANCA-associated vasculitides. Nature Clinical Practice Rheumatology 2:12, 661-670
CrossRef217
Christian Pagnoux, Boris Bienvenu, Loïc Guillevin. (2006) The spectrum of granulomatous vasculitides. Future Rheumatology 1:6, 729-750
CrossRef218
Frederick WK Tam. (2006) Current pharmacotherapy for the treatment of crescentic glomerulonephritis. Expert Opinion on Investigational Drugs 15:11, 1353-1369
CrossRef219
Tahmina Rahman, Lorraine Harper. (2006) Plasmapheresis in nephrology: an update. Current Opinion in Nephrology and Hypertension 15:6, 603-609
CrossRef220
S. Elitok, W. Schneider, F. Luft, R. Kettritz. (2006) Progredientes Nierenversagen mit Hautulkus und Nasenwurzeltumor. Der Nephrologe 1:4, 260-262
CrossRef221
Kan Saiga, Kazuhiro Tokunaka, Eiji Ichimura, Eriko Toyoda, Fuminori Abe, Minako Yoshida, Hiroshi Furukawa, Masato Nose, Masao Ono. (2006) NK026680, a novel suppressant of dendritic cell function, prevents the development of rapidly progressive glomerulonephritis and perinuclear antineutrophil cytoplasmic antibody in SCG/Kj mice. Arthritis & Rheumatism 54:11, 3707-3715
CrossRef222
Marcia S. Genta, Robert M. Genta, Cem Gabay. (2006) Systemic Rheumatoid Vasculitis: A Review. Seminars in Arthritis and Rheumatism 36:2, 88-98
CrossRef223
K. G. C. Smith, R. B. Jones, S. M. Burns, D. R. W. Jayne. (2006) Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment. Arthritis & Rheumatism 54:9, 2970-2982
CrossRef224
Eisha Mubashir, M Mubashir Ahmed, Samina Hayat, Shahnila Latif, Maureen Heldmann, Seth Mark Berney. (2006) Wegener Granulomatosis: A Case Report and Update. Southern Medical Journal 99:9, 977-988
CrossRef225
Xavier Bosch, Antonio Guilabert, Josep Font. (2006) Antineutrophil cytoplasmic antibodies. The Lancet 368:9533, 404-418
CrossRef226
Pasha Sarraf, Jonathan Kay, Robert P. Friday, Anthony M. Reginato. (2006) Wegener’s granulomatosis: Is biologic therapy useful?. Current Rheumatology Reports 8:4, 303-311
CrossRef227
Michael J. Dillon. (2006) Vasculitis treatment – new therapeutic approaches. European Journal of Pediatrics 165:6, 351-357
CrossRef228
Renato Alberto Sinico, Lucafrancesco Di Toma, Umberto Maggiore, Cinzia Tosoni, Paolo Bottero, Ettore Sabadini, Gaia Giammarresi, Bruno Tumiati, Gina Gregorini, Alberto Pesci, Stefano Monti, Genesio Balestrieri, Giovanni Garini, Filomena Vecchio, Carlo Buzio. (2006) Renal Involvement in Churg-Strauss Syndrome. American Journal of Kidney Diseases 47:5, 770-779
CrossRef229
Christian Pagnoux, Nicolas Kluger, Camille Francès, Loïc Guillevin. (2006) Cutaneous granulomatous vasculitis and extravascular granulomas. Expert Review of Dermatology 1:2, 315-326
CrossRef230
Nima Pakrou, Dinesh Selva, Igal Leibovitch. (2006) Wegener’s Granulomatosis: Ophthalmic Manifestations and Management. Seminars in Arthritis and Rheumatism 35:5, 284-292
CrossRef231
Peter K Wung, John H Stone. (2006) Therapeutics of Wegener's granulomatosis. Nature Clinical Practice Rheumatology 2:4, 192-200
CrossRef232
Kenneth C. Gorson. (2006) Therapy for Vasculitic Neuropathies. Current Treatment Options in Neurology 8:2, 105-117
CrossRef233
Norman Latov, Kenneth C. Gorson, Thomas H. Brannagan, Roy L. Freeman, Slobodan Apostolski, Alan R. Berger, Walter G. Bradley, Chiara Briani, Vera Bril, Neil A. Busis, Didier P. Cros, Marinos C. Dalakas, Peter D. Donofrio, P. James B. Dyck, John D. England, Morris A. Fisher, David N. Herrmann, Daniel L. Menkes, Zarife Sahenk, Howard W. Sander, William J. Triggs, Jean Michel Vallat. (2006) Diagnosis and Treatment of Chronic Immune-mediated Neuropathies. Journal of Clinical Neuromuscular Disease 7:3, 141-157
CrossRef234
Gary S Hoffman, Carol A Langford. (2006) Can methotrexate replace cyclophosphamide in the treatment of a subset of Wegener's granulomatosis and microscopic polyangiitis?. Nature Clinical Practice Rheumatology 2:2, 70-71
CrossRef235
Eamonn S. Molloy, Carol A. Langford. (2006) Advances in the Treatment of Small Vessel Vasculitis. Rheumatic Disease Clinics of North America 32:1, 157-172
CrossRef236
NAOMI TSURIKISAWA. (2006) Nihon Naika Gakkai Zasshi 95:8, 1493-1500
CrossRef237
Bernhard Hellmich, Peter Lamprecht, Wolfgang L Gross. (2006) Advances in the therapy of Wegenerʼs granulomatosis. Current Opinion in Rheumatology 18:1, 25-32
CrossRef238
Dayna J. Groskreutz, Jess Mandel. 2006. Pulmonary Vasculitis. , 237-253.
CrossRef239
Rapha??le Seror, Alfred Mahr, Jacky Ramanoelina, Christian Pagnoux, Pascal Cohen, Lo??c Guillevin. (2006) Central Nervous System Involvement in Wegener Granulomatosis. Medicine 85:1, 53-65
CrossRef240
(2005) Case 28-2005: A Case of Systemic Necrotizing Vasculitis. New England Journal of Medicine 353:23, 2516-2516
Full Text241
Greg A Schaublin, Clement J Michet, P James B Dyck, Ted M Burns. (2005) An update on the classification and treatment of vasculitic neuropathy. The Lancet Neurology 4:12, 853-865
CrossRef242
C. C. MOK. (2005) Can survival of systemic lupus erythematosus be further improved?. APLAR Journal of Rheumatology 8:3, 159-164
CrossRef243
Peggy W.G. du Buf-Vereijken, Amanda J.W. Branten, Jack F.M. Wetzels. (2005) Idiopathic Membranous Nephropathy: Outline and Rationale of a Treatment Strategy. American Journal of Kidney Diseases 46:6, 1012-1029
CrossRef244
C. Metzler, B. Hellmich, A. Gause. (2005) Neue Therapiekonzepte bei Vaskulitiden und Kollagenosen. Der Internist 46:12, 1347-1353
CrossRef245
M. S. Joy. (2005) A pilot study using mycophenolate mofetil in relapsing or resistant ANCA small vessel vasculitis. Nephrology Dialysis Transplantation 20:12, 2725-2732
CrossRef246
Surinder K Jindal, Ritesh Agarwal. (2005) Autoimmunity and interstitial lung disease. Current Opinion in Pulmonary Medicine 11:5, 438-446
CrossRef247
Anne Bourgarit, Philippe Le Toumelin, Christian Pagnoux, Pascal Cohen, Alfred Mahr, V??ronique Le Guern, Luc Mouthon, Lo??c Guillevin. (2005) Deaths Occurring During the First Year After Treatment Onset for Polyarteritis Nodosa, Microscopic Polyangiitis, and Churg-Strauss Syndrome. Medicine 84:5, 323-330
CrossRef248
Renato A. Sinico, Lucafrancesco Di Toma, Umberto Maggiore, Paolo Bottero, Antonella Radice, Cinzia Tosoni, Chiara Grasselli, Laura Pavone, Gina Gregorini, Stefano Monti, Micol Frassi, Filomena Vecchio, Caterina Corace, Emanuela Venegoni, Carlo Buzio. (2005) Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome. Arthritis & Rheumatism 52:9, 2926-2935
CrossRef249
Christopher E Collins, Francisco P Quismorio. (2005) Pulmonary involvement in microscopic polyangiitis. Current Opinion in Pulmonary Medicine 11:5, 447-451
CrossRef250
J.J. Ríos Blanco, J. Gómez Cerezo, E. Vázquez Muñoz, I. Suárez García, M. López Rodríguez, L. Yébenes Gregorio, I. Torres Sánchez, F.J. Barbado Hernández. (2005) Estudio clínico-biológico y radiológico de la granulomatosis de Wegener en un hospital universitario. Revista Clínica Española 205:8, 367-373
CrossRef251
Kirsten De Groot, Niels Rasmussen, Paul A. Bacon, Jan Willem Cohen Tervaert, Conleth Feighery, Gina Gregorini, Wolfgang L. Gross, Raashid Luqmani, David R. W. Jayne, . (2005) Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis & Rheumatism 52:8, 2461-2469
CrossRef252
Irina Buhaescu, Adrian Covic, Jeremy Levy. (2005) Systemic Vasculitis: Still a Challenging Disease. American Journal of Kidney Diseases 46:2, 173-185
CrossRef253
Ulrich Specks. (2005) Methotrexate for Wegener's granulomatosis: What is the evidence?. Arthritis & Rheumatism 52:8, 2237-2242
CrossRef254
MARK A LITTLE, CHARLES D PUSEY. (2005) Glomerulonephritis due to antineutrophil cytoplasm antibody-associated vasculitis: An update on approaches to management. Nephrology 10:4, 368-376
CrossRef255
Eric S. White, Carol A. Langford, Henry D. Tazelaar, Joseph P. Lynch. (2005) Management of Wegener Granulomatosis. Clinical Pulmonary Medicine 12:4, 220-231
CrossRef256
Philip Seo, Yuan-I. Min, Janet T. Holbrook, Gary S. Hoffman, Peter A. Merkel, Robert Spiera, John C. Davis, Steven R. Ytterberg, E. William St. Clair, W. Joseph McCune, Ulrich Specks, Nancy B. Allen, Raashid A. Luqmani, John H. Stone, . (2005) Damage caused by Wegener's granulomatosis and its treatment: Prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET). Arthritis & Rheumatism 52:7, 2168-2178
CrossRef257
E. Benenson, J. W. U. Fries, B. Heilig, M. Pollok, A. Rubbert. (2005) High-dose azathioprine pulse therapy as a new treatment option in patients with active Wegener’s granulomatosis and lupus nephritis refractory or intolerant to cyclophosphamide. Clinical Rheumatology 24:3, 251-257
CrossRef258
P. ERIKSSON. (2005) Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab. Journal of Internal Medicine 257:6, 540-548
CrossRef259
Oemer N Goek, John H Stone. (2005) Randomized controlled trials in vasculitis associated with anti-neutrophil cytoplasmic antibodies. Current Opinion in Rheumatology 17:3, 257-264
CrossRef260
Carol A. Langford. (2005) How can relapses be detected and prevented in primary systemic small-vessel vasculitides?. Best Practice & Research Clinical Rheumatology 19:2, 307-320
CrossRef261
Bernhard Hellmich, W.L. Gross. (2005) Difficult to diagnose manifestations of vasculitis: Does an interdisciplinary approach help?. Best Practice & Research Clinical Rheumatology 19:2, 243-261
CrossRef262
Christian Pagnoux, Loïc Guillevin. (2005) How can patient care be improved beyond medical treatment?. Best Practice & Research Clinical Rheumatology 19:2, 337-344
CrossRef263
David Jayne. (2005) How to induce remission in primary systemic vasculitis. Best Practice & Research Clinical Rheumatology 19:2, 293-305
CrossRef264
E. Riera Alonso, A. Olivé Marqués. (2005) Vasculitis asociadas a anticuerpos anticitoplasma de neutrófilo. Medicine - Programa de Formación Médica Continuada Acreditado 9:31, 2016-2023
CrossRef265
Matthew D. Morgan, Caroline O.S. Savage. (2005) Vasculitis in the gastrointestinal tract. Best Practice & Research Clinical Gastroenterology 19:2, 215-233
CrossRef266
Gary S. Hoffman, John H. Stone, Carol Langford. (2005) Implications of antineutrophil cytoplasmic antibody status when switching to maintenance therapy. Arthritis & Rheumatism 53:1, 1-2
CrossRef267
The Wegener's Granulomatosis Etanercept Trial (WGET) Research Group. (2005) Etanercept plus Standard Therapy for Wegener's Granulomatosis. New England Journal of Medicine 352:4, 351-361
Full Text268
Michael C. Sneller. (2005) Rituximab and Wegener's granulomatosis: Are B cells a target in vasculitis treatment?. Arthritis & Rheumatism 52:1, 1-5
CrossRef269
Maria Kallenbach, Hongmei Duan, Troels Ring. (2005) Rituximab Induced Remission in a Patient with Wegener’s Granulomatosis. Nephron Clinical Practice 99:3, c92-c96
CrossRef270
Karina A. Keogh, Mark E. Wylam, John H. Stone, Ulrich Specks. (2005) Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis & Rheumatism 52:1, 262-268
CrossRef271
Christian Pagnoux, Lo??c Guillevin. (2005) Peripheral neuropathy in systemic vasculitides. Current Opinion in Rheumatology 17:1, 41-48
CrossRef272
J. Galle, S. Seibold. (2004) Therapie entz
ndlicher Nierenerkrankungen. Der Internist 45:12, 1388-1394
CrossRef273
DAVID JAYNE. (2004) Predictors of outcome in renal vasculitis. Nephrology 9:5, 254-255
CrossRef274
R. K. Weersma, F. T. M. Peters, L. E. Oostenbrug, A. P. Berg, M. Haastert, R. J. Ploeg, M. D. Posthumus, J. J. Homan van der Heide, P. L. M. Jansen, H. M. Dullemen. (2004) Increased incidence of azathioprine-induced pancreatitis in Crohn's disease compared with other diseases. Alimentary Pharmacology and Therapeutics 20:8, 843-850
CrossRef275
Michael P Collins, M Isabel Periquet. (2004) Non-systemic vasculitic neuropathy. Current Opinion in Neurology 17:5, 587-598
CrossRef276
Harold R. Collard, Marvin I. Schwarz. (2004) Diffuse alveolar hemorrhage. Clinics in Chest Medicine 25:3, 583-592
CrossRef277
Kouichi Hirayama, Masaki Kobayashi, Yuko Hashimoto, Joichi Usui, Yoshio Shimizu, Aki Hirayama, Keigyou Yoh, Kunihiro Yamagata, Sohji Nagase, Michio Nagata, Akio Koyama. (2004) Treatment with the purine synthesis inhibitor mizoribine for ANCA-associated renal vasculitis. American Journal of Kidney Diseases 44:1, 57-63
CrossRef278
A. D. Booth. (2004) Renal vasculitis--an update in 2004. Nephrology Dialysis Transplantation 19:8, 1964-1968
CrossRef279
Yuko Akioka, Motoshi Hattori, Hiroshi Kawaguchi, Katsumi Ito. (2004) A Case of Chronic Relapsing ANCA-associated Microscopic Polyangiitis Successfully Treated with Plasma Exchange. Therapeutic Apheresis and Dialysis 8:3, 223-226
CrossRef280
S. Weidner. (2004) ANCA-associated vasculitis with renal involvement: an outcome analysis. Nephrology Dialysis Transplantation 19:6, 1403-1411
CrossRef281
Carol A. Langford, Cheryl Talar-Williams, Michael C. Sneller. (2004) Mycophenolate mofetil for remission maintenance in the treatment of Wegener's granulomatosis. Arthritis & Rheumatism 51:2, 278-283
CrossRef282
Bernhard Hellmich, Wolfgang L Gross. (2004) Recent progress in the pharmacotherapy of Churg-Strauss syndrome. Expert Opinion on Pharmacotherapy 5:1, 25-35
CrossRef283
R. Christopher Walton, Emily D. Ashmore. (2003) Retinal vasculitis. Current Opinion in Ophthalmology 14:6, 413-419
CrossRef284
(2003) Maintenance Therapy for Vasculitis Associated with Antineutrophil Cytoplasmic Autoantibodies. New England Journal of Medicine 349:21, 2072-2073
Full Text285
Charles D. Pusey. (2003) Anti-glomerular basement membrane disease. Kidney International 64:4, 1535-1550
CrossRef286
Langford, Carol A., . (2003) Treatment of ANCA-Associated Vasculitis. New England Journal of Medicine 349:1, 3-4
Full Text
- Letters
